



INDUSTRY | COMMENT

JANUARY 15, 2010

RBC Capital Markets Corp.

Adam Greene (Analyst)
(212) 618-3266; adam.greene@rbccm.com

D. Dewey Steadman, CFA (Associate)
(212) 428-3012; dewey.steadman@rbccm.com

Companies Mentioned**Cephalon, Inc.**

(Nasdaq: CEPH, \$64.14; Sector Perform, Above Average Risk)

Endo Pharmaceuticals Holdings

(Nasdaq: ENDP, \$20.82; Sector Perform, Above Average Risk)

Forest Laboratories, Inc.

(NYSE: FRX, \$31.35; Underperform, Above Average Risk)

King Pharmaceuticals, Inc.

(NYSE: KG, \$12.97; Sector Perform, Above Average Risk)

Medicis Pharmaceutical Corp.

(NYSE: MRX, \$24.91; Outperform, Above Average Risk)

Mylan Inc.

(Nasdaq: MYL, \$17.87; Outperform, Above Average Risk)

Par Pharmaceutical Co., Inc.

(NYSE: PRX, \$26.17; Sector Perform, Above Average Risk)

Perrigo Company

(Nasdaq: PRGO, \$42.13; Outperform, Above Average Risk)

Teva Pharmaceutical Industries Limited

(Nasdaq: TEVA, \$59.02 Outperform, Above Average Risk)

Warner Chilcott plc

(Nasdaq: WCRX, \$28.53; Outperform, Above Average Risk)

Watson Pharmaceuticals Inc.

(NYSE: WPI, \$41.10; Outperform, Above Average Risk)

Pharmaceuticals**Analyzing Litigation Success Rates**

In this report we analyze over 370 court rulings since the beginning of the decade to establish litigation success rates by company, court and judge. We also look at other trends in the pharmaceutical industry such as at-risk launches, patent settlements and authorized generics. Based on our review, we conclude that while patent challenges by generics are extremely common, winning is not.

Below are the key conclusions from our analysis:

- Patent challenges remain on the rise with a record 65 new first-to-file lawsuits in 2009, up from 51 in the prior year and more than double the number just three years ago.
- Over the last decade, the overall success rate for the generic drug industry is 48% for cases that have gone to trial. However, the success rate increases to 76% when settlements are included. Over half of all cases are settled or dropped.
- Perrigo has the best overall litigation success rate, taking top honors in best overall success rate, best batting average in court and highest percent of cases settled/dropped. Watson has the second best overall success rate.
- The top three courts by volume -- NJ, DE and SDNY -- accounted for 69% of all decisions. Unfortunately, these courts have a combined success rate of just 36% for generics. However, just over half of the cases in these three courts get settled or dismissed.
- Four courts have never ruled against a generic --California-CD, New York-ED, Minnesota and Missouri-ED.
- The top five judges by volume accounted for 31% of the total decisions. These five judges ruled in favor of generics only 33% of the time. The total success rate, however, including settlements is 75%.
- Last year we saw six at-risk launches, up from four in the last few years. Teva remains the most likely to go at-risk with 12 of the 28 at-risk launches since 2002.
- The number of settlements in 2009 reached an all-time high of 54, up from 45 in the prior year. Settlements occur on average 47% of the time with Teva accounting for nearly one-third of all settlements. On the innovator side, Glaxo and Novartis have settled the most.
- We counted 25 authorized generics launched in 2009 compared to 18 in the prior year. However, more products are launching without an AG than in prior years.
- By our count, Watson has introduced the most AGs, nearly one fifth of the industry's total.

Priced as of prior trading day's market close, EST (unless otherwise noted).
All values in USD unless otherwise noted.
For Required Conflicts Disclosures, see Page 23.

Table of Exhibits

Exhibit 1: Litigation Summary	Page 3
Exhibit 2: First To File Lawsuits	Page 2
Exhibit 3: Generic Drug Industry: Litigation Success Rate	Page 3
Exhibit 4: Best Generic Challengers 2000-2009	Page 5
Exhibit 5: Legal Scorecard Summary 2000-2009	Page 5
Exhibit 6: Decisions By Court	Page 6
Exhibit 7: Decisions By Most Active Judge	Page 6
Exhibit 8: Number of At-Risk Launches 2003-2009	Page 7
Exhibit 9: At-Risk Launches 2008-2009	Page 7
Exhibit 10: Number of Patent Settlements 2003-2009	Page 8
Exhibit 11: Most Cases Settled (Generics), Most Likely to Settle, Most Cases Settled (Brand)	Page 9
Exhibit 12: Patents Settlements in 2009	Page 10
Exhibit 13: Estimated 30 Month Stay Expirations in 2010-01-08	Page 11
Exhibit 14: Top Five Authorized Generic Players 2000-2009	Page 12
Appendix A: Potential Launches 2010-2011	Page 14
Appendix B: Rulings By Judge 2000-2009 (Complete)	Page 15
Appendix C: Paragraph 4 Filings (Complete)	Page 16
Appendix D: Litigation Scorecard History 2000-2009 (Complete)	Page 22

Summary

Patent challenges remain on the rise, with 65 new first-to-file paragraph IV challenges initiated in 2009, which brings the total to over 300 active cases. In this report we analyze over 370 court rulings since the beginning of the decade to establish litigation success rates by company, court and judge. We also look at other relevant trends in the industry such as at-risk launches, patent settlements and authorized generics. Exhibit 1 below summarizes litigation trends over the past seven years.

Exhibit 1: Litigation Summary


	2003	2004	2005	2006	2007	2008	2009
Settlements	6	4	8	20	21	45	54
At-Risk Launches	2	5	3	4	4	4	6
First to File P4 Suits	13	15	24	27	43	51	65

Source: PACER, Company reports, RBC Capital Markets estimates

Paragraph IV Challenges

In recent years patent challenges have become the rule rather than the exception for generics. According to our database there are approximately 300 active first-to-file paragraph IV challenges, most of which have multiple filers. The incentive is clear: the first ANDA filer to make a paragraph IV certification receives 180 days of market exclusivity during which no other ANDA can be approved for that drug. With very little downside and huge upside, exclusivity is the driving force to the huge increase in first-to-file paragraph IV filings (exhibit 2).

Exhibit 2: First-to-File Lawsuits



Source: PACER, Company reports, RBC Capital Markets estimates.

The litigation process starts with the filing of an ANDA with a paragraph IV certification, an acknowledgment that patents exist but the generic doesn't infringe or the patents aren't valid. The FDA has 60 days to accept the ANDA filing and then the generic filer has 20 days to notify the patent holder of its paragraph IV filing. Paragraph IV certifications are required for all products with patents listed in the FDA's Orange Book (the official patent listing). The patent holder then has 45 days to sue in order to initiate a 30 month stay of FDA approval of the generic version (companies may sue after 45 days but no stay would be granted). The approval stay is lifted at the end of 30 months or after a court decision, whichever is earlier. Following the Medicare Modernization Act (MMA) in


December 2003, patent holders are entitled to only one 30 month stay and are not entitled to a stay if a patent is listed after an ANDA is pending at the FDA (a late-listed patent). The 30 month clock is important because at the end of the stay companies are free to receive FDA approval and launch their generic products. However, this would be considered an *at-risk* launch if there is no court decision prior to launch. As such, generic companies may be responsible for up to triple damages if their products are found to infringe after an *at-risk* launch.

As a result of the large incentive to be first-to-file, we expect every patented product to be challenged, regardless of its size, i.e., Rozerem. We believe that if a drug does not have a challenge it speaks to the difficulty of formulating that product (i.e., Lidoderm). We count around 65 new first-to-file lawsuits in 2009 up 27% from 2008, but nearly a three-fold increase since 2005 (exhibit 2).

Patent Challenge Success Rates

The question we are most frequently asked relates to the success rate of paragraph IV patent challenges. According to our database on over 370 resolved cases over the last decade, the outcome is fairly even, with generics winning 82 of the rulings compared to losing 89. Thus, **the overall success rate for the generic industry is 48%** based on court decisions. However, when you take into account patent settlements and cases that were dropped, the **success rate for generics jumps to 76%**, substantially in favor of challenging patents (exhibit 3). With 54% of all cases either settled or dropped, it's easy to see why generic firms focus on first-to-file opportunities. Settlements provide clarity for the company and shareholders and we see them as a win-win for the generic and brand company. As we discuss later in the report, there were 54 disclosed patent settlements last year, an all time high.

Exhibit 3: Generic Drug Industry: Litigation Success Rate



Source: PACER, Company reports, RBC Capital Markets estimates.

The Best Generic Challengers

The second most common question we get is which generic companies are the most successful at winning patent challenges. We have highlighted in exhibits 4 and 5 the track records over the past decade for companies with five or more resolved paragraph IV challenges.

Perrigo takes the top honors for best overall success rate (defined as winning or settling a case), highest percentage of cases won and the highest settlement percentage. To be fair, Perrigo has only won one case, Pepcid Complete, but favorably resolved its other seven cases. That said, in our opinion, a settlement is as good as a win for shareholders, or possibly even better as it eliminates uncertainty and legal costs. Of the generic companies that have at least one court decision, Perrigo is the most likely to settle its case with seven cases settled/dropped of eight that have concluded, followed by Watson with 29 of its 39 cases either settled or dropped.

Watson has the second best overall success rate, having settled/dropped almost three quarters of its cases. Sandoz had the second best track record for court outcomes, but this is boosted by the inclusion of Eon Labs. Excluding Eon from Sandoz's results, the company would be tied with Par, Impax and Actavis for second with a 67% success rate. The results are presented in the scorecard below.

Exhibit 4: Best Generic Challengers 2000-2009

Best Overall Success Rate		Cases Won As % of Decisions		Cases Lost As % of Decisions		Cases Settled/Dropped As % of Total P4s		Most Number Of Concluded P4 Cases	
Perrigo	100%	Perrigo	100%	Apotex	86%	Perrigo	88%	Teva	108
Watson	90%	Sandoz	79%	Ranbaxy	78%	Watson	74%	Watson	39
Sandoz	88%	Par	67%	Dr. Reddy's	78%	KV Pharm	71%	Mylan	25
Par	87%	Impax	67%	Sun	75%	Lupin	63%	Sandoz	24
KV Pharm	86%	Actavis	67%	Lupin	67%	Par	60%	Apotex	21
Impax	86%	Watson	60%	URL Pharma	67%	Impax	57%	Ranbaxy	19
Actavis	83%	Teva	53%	Mylan	56%	Sun	56%	Dr. Reddy's	18
Teva	78%	KV Pharm	50%	KV Pharm	50%	Teva	53%	Par	15
Lupin	75%	Mylan	44%	Teva	47%	Ranbaxy	53%	Impax	14
Sun	67%	Lupin	33%	Watson	40%	Dr. Reddy's	50%	Sun	9
Mylan	64%	URL Pharma	33%	Par	33%	Actavis	50%	Perrigo	8
Ranbaxy	63%	Sun	25%	Impax	33%	Sandoz	42%	Lupin	8
Dr. Reddy's	61%	Ranbaxy	22%	Actavis	33%	URL Pharma	40%	KV Pharm	7
URL Pharma	60%	Dr. Reddy's	22%	Sandoz	21%	Mylan	36%	Actavis	6
Apotex	43%	Apotex	14%	Perrigo	0%	Apotex	33%	URL Pharma	5

**Includes predecessor firms.*

Source: PACER, Company reports, RBC Capital Markets estimates

Exhibit 5: Legal Scorecard Summary 2000-2009

	Lost		Won		Dropped/ Settled		Success		Launched At Risk
		%		%		%	TOTAL	%	
Actavis	1	17%	2	33%	3	50%	6	83%	1
Apotex	12	57%	2	10%	7	33%	21	43%	1
Dr. Reddy's	7	39%	2	11%	9	50%	18	61%	0
Impax	2	14%	4	29%	8	57%	14	86%	0
KV Pharm	1	14%	1	14%	5	71%	7	86%	0
Lupin	2	25%	1	13%	5	63%	8	75%	0
Mylan	9	36%	7	28%	9	36%	25	64%	1
Par	2	13%	4	27%	9	60%	15	87%	1
Perrigo	0	0%	1	13%	7	88%	8	100%	1
Ranbaxy	7	37%	2	11%	10	53%	19	63%	0
Sandoz	3	13%	11	46%	10	42%	24	88%	6
Sun	3	33%	1	11%	5	56%	9	67%	2
Teva	24	22%	27	25%	57	53%	108	78%	13
URL Pharma	2	40%	1	20%	2	40%	5	60%	0
Watson	4	10%	6	15%	29	74%	39	90%	0

Source: PACER, Company reports, RBC Capital Markets estimates

Court Information

We have also reviewed our database to determine which districts are the best to try a case (exhibit 6). Three districts were responsible for nearly 70% of all court decisions -- New Jersey (35%), Delaware (21%) and the Southern District of New York (12%). The bad news for generics is that the combined historical success rate in these three districts is just 36%, which likely explains the 52% settlement rate in these districts. The most pro-generic courts include the Central District of California, the Eastern District of New York, Minnesota and the Eastern District of Missouri, having a perfect record of ruling in favor of generics every time.



Exhibit 6: Decisions By Court

	Ruled For Generics	Ruled Against Generics	Total Rulings	Generic Success Rate	Case Settled	Case Dismissed	Overall Generic Success Rate	Total Cases
California (Central District)	8	0	8	100%	9	0	100%	17
California (Northern District)	2	2	4	50%	2	0	67%	6
DC	3	2	5	60%	0	0	60%	5
Delaware	10	17	27	37%	46	8	79%	81
Florida (Southern District)	2	1	3	67%	4	0	86%	7
Georgia (Northern District)	0	0	0	NM	5	0	100%	5
Illinois (Northern District)	8	8	16	50%	6	1	65%	23
Indiana (Southern District)	1	5	6	17%	0	2	38%	8
Maryland	0	0	0	NM	2	0	100%	2
Massachusetts	0	3	3	0%	1	2	50%	6
Michigan (Eastern District)	2	2	4	50%	1	0	60%	5
Michigan (Western District)	0	0	0	NM	1	0	100%	1
Minnesota	2	0	2	100%	0	0	100%	2
Missouri (Eastern District)	1	0	1	100%	0	1	100%	2
New Jersey	27	47	74	36%	55	3	64%	132
New York (Eastern District)	2	0	2	100%	1	0	100%	3
New York (Southern District)	8	16	24	33%	22	1	66%	47
North Carolina (Eastern District)	0	0	0	NM	1	0	100%	1
North Carolina (Middle District)	0	1	1	0%	0	0	0%	1
Ohio (Southern District)	0	1	1	0%	2	0	67%	3
Pennsylvania (Eastern District)	1	3	4	25%	1	1	50%	6
Pennsylvania (Western District)	1	1	2	50%	1	0	67%	3
Virginia (Eastern District)	4	2	6	67%	0	0	67%	6
West Virginia (Northern District)	1	3	4	25%	1	0	40%	5

Source: PACER, Company reports, RBC Capital Markets estimates

Drilling down more to review how each judge ruled in the past. The top five judges accounted for 31% of the total decisions with Judges Farnan and Sleet in Delaware issuing the most decisions. The generic success rate for bench rulings from these five judges is 33%. The total success rate, however, including settlements is 75%.

When looking at judges that have issued five or more decisions (exhibit 7), the success rate for rulings for generics is just 37%. The total overall success rate for generics among these judges increases to 64% when including cases dropped or settled for this group of judges.

Exhibit 7: Decisions By Most Active Judges


Judge	District	Ruled For Generics	Ruled Against Generics	Total Rulings	Generic Success Rate	Case Settled	Case Dismissed	Overall Generic Success Rate	Total Cases
Joseph J. Farnan Jr	DE	6	10	16	38%	20	4	75%	40
Dennis M. Cavanaugh	NJ	7	4	11	64%	0	1	67%	12
John C. Lifland	NJ	3	7	10	30%	8	0	61%	18
Joel A. Pisano	NJ	4	5	9	44%	6	0	67%	15
Stanley R. Chesler	NJ	1	8	9	11%	2	0	27%	11
Sue L. Robinson	DE	3	5	8	38%	5	1	64%	14
Barbara S. Jones	NY-SD	3	5	8	38%	0	0	38%	8
Mary L. Cooper	NJ	1	5	6	17%	12	0	72%	18
Mariana R. Pfaelzer	CA-CD	5	0	5	100%	3	0	100%	8
Sidney H. Stein	NY-SD	2	3	5	40%	9	0	79%	14
David H. Coar	IL-ND	1	4	5	20%	4	0	56%	9
Sarah Evans Barker	IN-SD	1	4	5	20%	0	0	20%	5
Dickinson R. Debevoise	NJ	1	4	5	20%	0	0	20%	5
		38	64	102	37%	69	6	64%	177

Source: PACER, Company reports, RBC Capital Markets estimates

At-Risk launches

While at-risk launches get a lot of attention, they are still fairly uncommon. We define an at-risk launch as any launch without a lower court ruling. Last year we saw six at-risk launches, up from four in the last few years (exhibit 8). Teva is the most likely to launch at-risk, having launched 12 of the 28 at-risk launches over the last seven years. This is followed by Sandoz with six and Mylan, Par and Sun each launching two products at-risk.

Exhibit 8: Number of At-Risk Launches 2003-2009



Source: PACER, Company reports, RBC Capital Markets estimates.

Last year was the first year we did not see any at-risk launches of blockbuster products like Protonix, Pulmicort or Plavix that occurred in prior years. However, 2009 was unusual in that of the six at-risk launches, two were on very small drugs – Niravam and Xopenex solution – and the other four were settled after launch – Solodyn by both Teva and Sandoz, as well as Ortho Tri Cyclen Lo and Loprox Shampoo (exhibit 9). Settling after launch appears to be a new emerging trend with two in 2008 and four in 2009.

Exhibit 9: At-Risk Launches 2008-2009


Date	Drug	Generic	Comments
Jan-08	Protonix	Sun/Caraco	
Mar-08	Olux	Perrigo	
Mar-08	Ethyol	Sun/Caraco	Settled after launch
Nov-08	Pulmicort	Teva	Settled after launch
Mar-09	Solodyn	Teva	Settled after launch
Jan-09	Niravam	Par	Very small drug
Jul-09	Ortho Tri Cyclen Lo	Teva	Settled after launch
Aug-09	Solodyn	Sandoz	Settled after launch
Aug-09	Xopenex concentrate	Mylan	Very small drug
Nov-09	Loprox shampoo	Paddock	Settled after launch

Source: Company reports and RBC Capital Markets estimates.

Settlements

The number of settlements in 2009 reached an all-time high of 54, up from 45 in 2008 (exhibit 10). Settlements spiked in 2006 following the June 2006 decision by the Supreme Court to not hear the FTC’s appeal in *Schering Plough vs. Upsher-Smith*. This case questioned whether monetary payment from a brand company to a generic company was lawful. In 2009, legislation heated up to limit patent settlements and in October the Senate Judiciary Committee passed the Kohl Bill. The bill was eventually revised to make payments presumptively illegal rather than *per se* illegal. This allows generics and brands to defend their settlement as pro-competitive. It is difficult to say whether the activity in Washington had a direct impact on the number of settlements, but of the 54 cases, there were 10 settled in both the first and second quarter of 2009 and 17 in each of the final quarters of the year. Thus, there was no discernable up tick in settlements near year end.

Exhibit 10: Number of Patent Settlements 2003-2009



Source: PACER, Company reports, RBC Capital Markets estimates.

Despite the noise in Washington, we expect settlements to remain fairly common. For active paragraph IV firms with over five resolved cases, settlements occur on average 54% of the time. Teva accounts for almost 30% of all settlements but this is just 53% of their caseload (exhibit 11). Of all generics, Wockhardt tends to walk the most, settling all four of its patent challenges. We have also included in the exhibit 11 the innovator firms with the most patent settlements. GlaxoSmithKline and Novartis have each settled about 9% of the total.

Exhibit 11: Most Cases Settled (Generics), Most Likely to Settle, Most Cases Settled (Brand)

Generic	Settled/ Dropped	Total Cases	% Cases Settled	Generic	Settled/ Dropped	Total Cases	% Cases Settled	Brand	Number of Settlements	% of Total
Teva	57	108	53%	Wockhardt	4	4	100%	Glaxo	14	8.8%
Watson	29	39	74%	Orchid	2	2	100%	Novartis	14	8.8%
Sandoz	10	24	42%	Upsher Smith	2	2	100%	Schering-Plough	12	7.5%
Ranbaxy	10	19	53%	Alcon	1	1	100%	Forest	11	6.9%
Mylan	9	25	36%	Amneal	1	1	100%	Abbott	11	6.9%
Dr. Reddy's	9	18	50%	Bedford	1	1	100%	J&J	8	5.0%
Par	9	15	60%	Breath	1	1	100%	Wyeth	8	5.0%
Impax	8	14	57%	Covidien	1	1	100%	Pfizer	7	4.4%
Apotex	7	21	33%	Cypress Pharma	1	1	100%	Shire	7	4.4%
Perrigo	7	8	88%	Tolmar	1	1	100%	Cephalon	6	3.8%
Sun	5	9	56%	Perrigo	7	8	88%	Medicis	6	3.8%
Lupin	5	8	63%	Anchen	3	4	75%	Purdue	6	3.8%
KV Pharm	5	7	71%	Watson	29	39	74%	Warner Chilcott	6	3.8%
Wockhardt	4	4	100%	KV Pharm	5	7	71%	Sanofi	5	3.1%
Actavis	3	6	50%	Glenmark	2	3	67%	AstraZeneca	3	1.9%

Source: PACER, Company reports, RBC Capital Markets estimates.

Exhibit 12: Patent Settlements in 2009

Settled	Brand	Generic	Drug	Launch Date
1/12/09	Loestrin-24 Fe	Warner Chilcott	Watson	01/22/2014
1/12/09	Femcon Fe	Warner Chilcott	Watson	NLT 1/1/2013
2/11/09	Lotrel	Novartis	Par	1Q11
2/19/09	Opana ER 7.5mg 15mg	Endo	Actavis	40739
3/6/09	Naprelan	Elan	Watson	41800
3/10/09	Xopenex	Sepracor	Barr	41322
3/18/09	Solodyn	Medicis	Teva	Nov 2011
3/27/09	Razadyne	J&J	KV Pharma	NA
3/27/09	Razadyne ER	J&J	KV Pharma	NA
3/30/09	Razadyne	J&J	Sandoz	NA
4/8/09	Clarinx	Schering-Plough	Mylan	07/01/2012
4/8/09	Clarinx	Schering-Plough	Sandoz	07/01/2012
4/14/09	Vanos	Medicis	Perrigo	12/15/2013
4/16/09	Oxycontin	Purdue	Actavis	TBD
4/21/09	Rythmol SR	Glaxo	Par	01/01/2011
4/23/09	Effexor XR caps	Wyeth	Lupin	06/01/2011
4/24/09	Lybrel	Wyeth	Watson	05/22/2010
4/29/09	Comtan	Novartis/Orion	Wockhardt	09/30/2012
4/29/09	Stalevo	Novartis/Orion	Wockhardt	09/30/2012
5/18/09	Effexor XR caps	Wyeth	Wockhardt	06/01/2012
7/9/09	Eloxatin	Sanofi	Ebewe	NA
7/10/09	Lexapro	Forest	Sun Pharm	10/14/2012
7/24/09	Ortho Tri Cyclen Lo	J&J	Teva	12/31/2015
8/3/09	Ethylol	Medimmune	Sun Pharm	NA
8/11/09	Clarinx RediTabs	Schering-Plough	Orchid	01/01/2012
8/11/09	Clarinx	Schering-Plough	Orchid	07/01/2012
8/11/09	Plavix	Bristol-Myers	Watson	TBD
8/30/09	Oxycontin	Purdue	Apotex	TBD
9/9/09	Lotrel	Novartis	Lupin	NA
9/11/09	Namenda	Forest	Apotex	04/11/2015
9/11/09	Namenda	Forest	Upsher Smith	01/11/2015
9/11/09	Namenda	Forest	Amneal	01/11/2015
9/11/09	Namenda	Forest	Wockhardt	01/11/2015
9/14/09	Carbatrol	Shire	Teva	NA
9/14/09	Lybrel	Wyeth	Sandoz	NA
9/24/09	Lotrel	Novartis	Dr. Reddy	NA
9/24/09	Lotrel	Novartis	Cobalt	NA
10/5/09	Flomax	Astellas	Impax	02/10/2003
10/8/09	Namenda	Forest	Sun Pharm	01/11/2015
10/13/09	Adderall XR	Shire	Sandoz	When approved
10/14/09	Vfend	Pfizer	Mylan	1Q11
10/15/09	Duac	Stiefel	Perrigo	TBD
10/19/09	Namenda	Forest	Cobalt	42015
10/27/09	Oxytrol	Watson	Barr	42120
11/5/09	Namenda	Forest	Teva	42015
11/12/09	Fentora	Cephalon	Teva	Oct 2018
11/16/09	Loprox	Medicis	Glenmark	41623
11/16/09	Vanos	Medicis	Glenmark	41623
11/30/09	Tricor 145mg	Abbott	Teva	40630
12/8/09	Effexor XR caps	Wyeth	Mylan	40695
12/8/09	Arthrotec	Pfizer	Teva	NA
12/9/09	Loprox shampoo	Medicis	Paddock	NA
12/14/09	Namenda	Forest	Dr. Reddy	42015
12/14/09	Namenda	Forest	Lupin	42015

Source: PACER, Company reports, RBC Capital Markets estimates.



30 Month Stays

As discussed earlier the expiration of the 30 month stay is important since the FDA is cleared to approve the generic at the end of the stay. At that point, the generic firm can decide to launch *at-risk* or wait for resolution of the litigation. Also, as previously discussed, *at-risk* launches are fairly uncommon. However, they do present an overhang in that the patent litigation can go in the innovator's favor after launch, leaving the generic company liable for damages. In exhibit 13, we highlight upcoming 30-month stay expirations in 2010.

Exhibit 13: Estimated 30 Months Stays Expirations in 2010

Drug	Dose	Brand Co.	Est. First Filer	Date Sued	30 Month Stay
Boniva	2.5 and 150 mg	Roche	Shared-Multiple	9/7/07	1/24/10
Zegerid caps	20/1100mg, 40/1100mg, 20/1680mg	Santarus	Par	9/13/07	1/30/10
Focalin XR	5, 10, 20 mg	Novartis	Teva	9/14/07	1/31/10
Focalin XR	15 mg	Novartis	Par	10/4/07	2/20/10
Zanaflex (caps)	2, 4, 6 mg	Acorda	Apotex	10/11/07	2/28/10
Avinza	30, 45, 60, 75, 90, 120 mg	King	Actavis	10/18/07	3/4/10
Allegra D-24	180 mg/240 mg	Aventis	Dr. Reddy's	10/26/07	3/14/10
Asacol	400 mg	P&G	Roxane	10/26/07	3/14/10
Combivir	150 mg/300 mg	GlaxoSmithKline	Teva	11/2/07	3/20/10
Luxiq	0.12%	Connetics	Perrigo/Pentech	11/6/07	3/24/10
Taxotere	20mg/2ml, 80mg/8ml, 160mg/16ml	Sanofi-Aventis	Hospira 505b2	11/9/07	3/28/10
Stalevo 100, 150	25/100/200 mg and 37.5/150/200 mg	Novartis/Orion	Sun Pharm	11/13/07	3/31/10
Opana ER	5, 10, 20, 40 mg	Endo	Impax	11/15/07	4/2/10
Zymar	0.3% solution drops	Allergan	Apotex	11/29/07	4/16/10
Zetia	10 mg	Merck	Glenmark	3/22/07	4/24/10
Tarka	4/240mg, 2/240mg, 2/180mg, 1/240mg	Abbott	Glenmark	12/7/07	4/28/10
Detrol LA	2, 4 mg	Pfizer	Teva	12/12/07	4/29/10
Strattera	10, 18, 25, 40, 60, 80, 100mg	Eli Lilly	Shared-Multiple	8/9-9/5/2007	5/6/10
Zegerid suspension	40/1680mg per packet	Santarus	Par	12/20/07	5/13/10
Abilify	2, 5, 10, 15, 20, 30 mg	Bristol-Myers Squibb	Shared-Multiple	3/2/07	5/15/10
Abilify ODT	10, 15, 20, 30 mg	Bristol-Myers Squibb	Barr	3/16/07	5/15/10
Argatroban Injection	100 mg/ml	Encysive	Barr	12/28/07	5/19/10
Equetro	200, 300 mg	Validus Pharmaceuticals	Actavis	1/17/08	6/3/10
Clobex shampoo	0.05%	Galderma	Actavis	2/21/08	7/8/10
Avodart	0.05 mg	GlaxoSmithKline	Barr	2/25/08	7/11/10
Abilify Oral Solution	1 mg/ml	Bristol-Myers Squibb	Teva	3/31/08	8/15/10
Entocort	3mg	AstraZeneca	Barr	5/22/08	10/8/10
Fentora	.1, .2, .3, .4, .6, .8mg	Cephalon	Watson	6/2/08	10/20/10
Alimta	500mg/vial	Eli Lilly	Teva	6/5/08	10/23/10
Accolate	10mg, 20mg	AstraZeneca	Dr. Reddy	6/27/08	11/12/10
Opana ER	7.5mg, 15mg	Endo	Actavis	7/11/08	11/27/10
Zometa (inj)	4mg base/5mL, 5mg base/100mL	Novartis	Teva	7/24/08	12/9/10
Uroxatral	10 mg	Sanofi-Aventis	Shared	9/21/07	12/10/10
Sensipar	30, 60, 90mg	Amgen	Teva	7/25/08	12/11/10
Actoplus Met	15/500mg and 15/850mg	Eli Lilly/Takeda	Mylan	8/5/08	12/22/10
Taxotere	40mg/ml, 20mg/0.5ml, 80mg/2ml	Sanofi-Aventis	Apotex 505b2	8/8/08	12/26/10
Opana ER	30mg	Endo	Actavis	7/11/08	12/29/10
Ambien CR	12.5mg	Sanofi-Aventis	Anchen	Filed 1/19/06	Not Sued
Ambien CR	6.25mg	Sanofi-Aventis	Actavis	Filed 2/24/06	Not Sued
Atacand	4, 8, 16, and 32 mg	AstraZeneca	Sandoz	Filed 12/22/06	Not Sued
Atacand HCT	16/12.5, 32/12.5 mg	AstraZeneca	Mylan	Filed 12/22/06	Not Sued
Elestat	0.05%	Inspire/Allergan	Sandoz	Filed 10/14/08	Not Sued
Exforge	10/160mg	Novartis	Par	Filed 10/1/07	Not Sued
Exforge	5/160mg	Novartis	Par	Filed 10/22/07	Not Sued
Exforge	10/320mg	Novartis	Par	Filed 11/9/07	Not Sued
Exforge	5/320mg	Novartis	Par	Filed 11/26/07	Not Sued
Lescol XL	80mg	Novartis	Par	Filed 3/15/07	Not Sued
Requip XL	2, 3, 4, 8, 12mg	GlaxoSmithKline	Impax, Actavis	Filed 10/14/08	Not Sued
Rhinocort spray	0.032 mg (32 mcg)/spray	AstraZeneca	Apotex	Filed 5/14/07	Not Sued

Source: PACER, Company reports, RBC Capital Markets estimates.



Authorized Generics

There were roughly 25 authorized generics (AG) launched in 2009, up from about 18 in the prior year. However, one trend we have noticed recently is an increasing number of generics launched without an AG. We counted around a dozen generics launched last year with no AG compared to just six in 2008. We believe this is highly correlated to the increase in settlement agreements a few years ago. Some of the recent high-profile generic launches without AGs include Adderall XR, Pulmicort and Mirapex to name just a few. We see this as a very positive trend for the generic pharmaceutical industry and expect an increase in the number of AG-free launches in the future. Launching without an AG can generate almost three times the revenue and approximately 3.7x more profit than launching with an AG.

Notwithstanding the favorable economic impact an AG-less launch presents, we still expect AGs to remain part of the industry. While margins are small, an AG presents an attractive ROI for the company launching the AG. Of the 96 AGs we count launched by independent generic firms since 2000, Watson was involved in close to 20% with Prasco close behind (exhibit 14). We also expect generic arms of big pharma companies such as J&J's Patriot, Pfizer's Greenstone and Sanofi's Winthrop to remain active players in the market going forward.

Exhibit 14: Top Five Authorized Generic Players 2000-2009

Authorized Generics	Total
Watson	19
Prasco	17
Par	9
Sandoz	9
Ranbaxy	4
Industry Total	96

Source: PACER, Company reports, RBC Capital Markets estimates.

APPENDIX

Appendix A: Potential Launches 2010-2011

Date of Gx Entry	Brand Company	Drug	Generic Company	Type
TBD	Sanofi	Ambien CR	Anchen, Par	Patent
TBD	Merck	Primaxin IV	Multiple	Patent Expiration
TBD	Warner Chilcott	Femhrt	Barr	Settlement Launch
3/1/10	Meda	Astelin	Apotex	Settlement Launch
3/2/10	Boehringer	Flomax	Ranbaxy, Impax	Settlement Launch
4/6/10	Merck	Cozaar/Hyzaar	Multiple	Patent Expiration
4/20/10	GlaxoSmithKline	Coreg CR	Mutual	Data Exclusivity
4/27/10	Boehringer	Flomax	Multiple	Patent Expiration
5/22/10	Wyeth	Lybrel	Watson	Settlement Launch
6/1/10	Wyeth	Effexor XR caps	Teva	Settlement Launch
6/27/10	AstraZeneca	Arimidex	Multiple	Patent Expiration
7/1/10	Novartis	Exelon	Dr. Reddy's, Sun	Settlement Launch
8/28/10	Meda	Astelin	Cobalt	Settlement Launch
9/1/10	Valeant	Diastat	Par/Barr	Settlement Launch
9/23/10	Medicines Co.	Angiomax	Teva	At Risk
11/15/10	Eli Lilly	Gemzar	Multiple	Patent invalidated
11/25/10	Pfizer	Aricept	Teva, Ranbaxy	Patent Expiration
1/1/11	GlaxoSmithKline	Rythmol SR	Par	Settlement Launch
1/1/11	Novartis	Lotrel	Par	Settlement Launch
1/17/11	Takeda	Actos	Multiple	Patent Expiration
1/19/11	Wyeth	Protonix	Multiple	Patent Expiration
1Q11	Pfizer	Vfend	Mylan	Settlement Launch
1Q11	Novartis	Exelon	Watson	Settlement Launch
3/22/11	Pfizer	Xalatan	Multiple	Patent Expiration
3/28/11	Abbott	Tricor 145mg	Teva	Settlement Launch
6/1/11	Wyeth	Effexor XR caps	Impax	Settlement Launch
6/1/11	Wyeth	Effexor XR caps	Anchen	Settlement Launch
6/1/11	Wyeth	Effexor XR caps	Lupin	Settlement Launch
6/15/11	Sanofi	Nasacort AQ	Barr	Settlement Launch
6/20/11	J&J	Levaquin	Multiple	Patent Expiration
7/1/11	Bayer	Yaz	Barr	Settlement Launch
7/15/11	Endo	Opana ER 7.5mg 15mg	Actavis	Settlement Launch
10/23/11	Eli Lilly	Zyprexa	Multiple	Patent Expiration
10/23/11	Eli Lilly	Symbyax	Multiple	Patent Expiration
11/1/11	Medicis	Solodyn	Impax	Settlement Launch
11/1/11	Medicis	Solodyn	Teva	Settlement Launch
11/17/11	Bristol Myers	Plavix	Multiple	Settlement Launch
11/30/11	Pfizer	Caduet	Ranbaxy	Settlement Launch
11/30/11	Pfizer	Lipitor	Ranbaxy	Settlement Launch
2011E	Novartis	Femara	Mylan	Settlement Launch

Source: PACER, Company reports, RBC Capital Markets estimates.

Appendix B: Rulings By Judge 2000-2009 (Complete)

	Ruled For		Ruled Against	
	Generics	Generics	Settled	Dismissed
California (Central District)	8	0	9	0
Cormac J. Carney	0	0	1	0
James V. Selna	1	0	5	0
Mariana R. Pfaelzer	5	0	3	0
Robert J. Timlin	2	0	0	0
California (Northern District)	2	2	2	0
Charles R. Breyer	0	1	0	0
James Ware	0	0	1	0
Marilyn Patel	1	0	0	0
Maxine M. Chesney	0	1	1	0
Vaughn R. Walker	1	0	0	0
DC	3	2	0	0
John D. Bates	0	2	0	0
Reggie B. Walton	1	0	0	0
Ricardo M. Urbina	1	0	0	0
Royce C. Lamberth	1	0	0	0
Delaware	10	17	46	8
Gregory M. Sleet	0	2	19	3
Joseph J. Farnan Jr	6	10	20	4
Kent A. Jordan	1	0	2	0
Sue L. Robinson	3	5	5	1
Florida (Southern District)	2	1	4	0
Adalberto Jordan	1	1	0	0
Daniel T. K. Hurley	0	0	2	0
Shelby Highsmith	0	0	1	0
Wilkie D. Ferguson Jr.	1	0	0	0
William P. Dimitrouleas	0	0	1	0
Illinois (Northern District)	8	8	6	1
David H. Coar	1	4	4	0
Geraldine Soat Brown	0	0	1	0
James M. Rosenbaum	0	1	0	0
Joan B. Gottschall	1	0	0	0
Joan H. Lefkow	0	1	0	0
John W. Darrah	2	0	0	1
Rebecca R. Pallmeyer	1	0	0	0
Richard A. Posner	1	1	1	0
Robert W. Gettleman	0	1	0	0
Ronald A. Guzman	1	0	0	0
Wayne R. Anderson	1	0	0	0
Georgia (Northern District)	0	0	5	0
Thomas W. Thrash Jr.	0	0	1	0
William S. Duffey, Jr	0	0	3	0
J. Owen Forrester	0	0	1	0
Indiana (Southern District)	1	5	0	2
Larry J. McKinney	0	0	0	1
Richard Young	0	1	0	1
Sarah Evans Barker	1	4	0	0
Maryland	0	0	2	0
William D Quarles, Jr	0	0	1	0
Marvin J. Garbis	0	0	1	0
Massachusetts	0	3	1	2
Douglas P. Woodlock	0	0	1	0
Joseph L. Tauro	0	1	0	1
Reginald C. Lindsay	0	0	0	1
Richard G. Steams	0	2	0	0
Michigan (Eastern District)	2	2	1	0
Avern Cohn	0	1	0	0
Bernard A Friedman	1	0	1	0
George Caram Steeh	1	1	0	0
Michigan (Western District)	0	0	1	0
Paul L Maloney	0	0	1	0
Minnesota	2	0	0	0
Ann D. Montgomery	1	0	0	0
Michael J. Davis	1	0	0	0
Missouri (Eastern District)	1	0	0	1
Donald J. Stohr	0	0	0	1
Rodney W. Sippel	1	0	0	0
New York (Eastern District)	2	0	1	0
David G. Trager	1	0	1	0
Nina Gershon	1	0	0	0
New York (Southern District)	8	16	22	1
Barbara S. Jones	3	5	0	0
Colleen McMahon	1	0	0	0
Charles L. Briant	1	0	0	0
Denise Cote	0	1	0	0
Gerard E. Lynch	0	2	0	0
Harold Baer	0	0	3	0
Kimba Wood	0	0	1	0
Laura Taylor Swain	0	0	1	0
Lawrence M. McKenna	0	2	1	0
Loretta A. Preska	0	0	1	0
Lewis A. Kaplan	0	0	0	1
P. Kevin Castel	0	0	1	0
Richard C. Casey	0	1	0	0
Richard J. Howell	0	0	1	0
Richard J. Sullivan	0	0	1	0
Robert P. Patterson	0	1	0	0
Setphen C. Robinson	0	0	2	0
Sidney H. Stein	2	3	9	0
Victor Marrero	0	0	1	0
William H. Pauley III	1	1	0	0
New Jersey	27	47	55	3
Harold A. Ackerman	0	2	2	1
Dennis M. Cavanaugh	7	4	0	1
Dickinson R. Debevoise	1	4	0	0
Faith S. Hochberg	1	0	1	0
Freda Wolfson	1	1	2	0
Garrett E. Brown, Jr	1	2	4	0
Joel A. Pisano	4	5	6	0
John C. Lifland	3	7	8	0
John W. Bissell	1	1	1	0
Jose L. Linares	1	1	0	1
Joseph A. Greenaway Jr	2	0	4	0
Katherine S. Hayden	1	1	1	0
Mary L. Cooper	1	5	12	0
Noel L. Hillman	0	0	1	0
Peter G. Sheridan	2	1	3	0
Renee Marie Bumb	0	4	1	0
Stanley R. Chesler	1	8	2	0
Susan D. Wigenton	0	0	2	0
Tonianne J. Bongiovanni	0	0	1	0
William J. Martini	0	1	3	0
William H. Walls	0	0	1	0
North Carolina (Middle District)	0	1	0	0
James A. Beaty	0	1	0	0
North Carolina (Eastern District)	0	0	1	0
James C. Dever, III	0	0	1	0
Ohio (Southern District)	0	1	2	0
Edmund A. Sargus	0	0	1	0
Michael R. Barrett	0	1	1	0
Pennsylvania (Eastern District)	1	3	1	1
Michael M. Bayson	0	2	0	0
Paul S. Diamond	0	0	1	0
R. Barclay Surrick	1	1	0	1
Pennsylvania (Western District)	1	1	1	0
Gary L. Lancaster	0	0	1	0
Terrence F. McVerry	1	1	0	0
Virginia (Eastern District)	4	2	0	0
Henry C. Morgan Jr.	2	0	0	0
Richard L. Williams	0	1	0	0
Robert E. Payne	1	0	0	0
Robert G. Doumar	0	1	0	0
T. S. Ellis, III	1	0	0	0
West Virginia (Northern District)	1	3	1	0
Irene M. Keeley	1	2	1	0
William K. Sessions	0	1	0	0

Source: PACER, Company reports, RBC Capital Markets estimates.



Appendix C: Paragraph IV Filings (Complete)

Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Abilify	2, 5, 10, 15, 20, 30 mg	Teva, Sandoz, Barr,	Multiple	3/2/2007 (earliest)	3:07-cv-01000	NJ	Mary L. Cooper	Pending	Teva (3/07), Sandoz (3/07), Barr (3/07), Apotex (3/07), Sun (3/30), Synthron (4/07)
		Apotex, Synthron							
Abilify Oral Solution	1 mg/ml	Teva	2/15/08	3/31/08	3:08-cv-01583	NJ	Mary L. Cooper	Pending	Teva (3/08, 10/09)
Accolate	10mg, 20mg	Dr. Reddy	5/14/08	6/27/08	3:08-cv-03237	NJ	Mary L. Cooper	Pending	Dr. Reddy (6/08)
Aciphex	20 mg	Teva, Dr. Reddy	NA	11/20/03	1:03-cv-09223	SD of NY	Gerard E. Lynch	Lost 5/07; Upheld 7/08	Dr. Reddys (11/03), Teva (11/03), Mylan (1/04)
Aceon	2, 4, 8 mg	Cobalt Pharma	6/23/06	8/8/06	1:06-cv-01856	ND of GA	Marvin H. Shoob	Settled 5/08	Cobalt (8/06, S-5/08)
Actonel	5, 30, 35 mg	Teva	7/2/04	8/13/04	1:04-cv-00940	DE	Joseph J. Farnan, Jr.	Lost 2/08; Upheld 5/09	Teva (8/04)
Actonel	75 mg	Teva	12/19/07	2/1/08	1:08-cv-00066	DE	Joseph J. Farnan, Jr.	Lost 2/08; Upheld 5/09	Teva (2/08)
Actonel with Calcium	35/500 mg	Teva	2/19/08	4/4/08	1:08-cv-00191	DE	Joseph J. Farnan, Jr.	Lost 2/08; Upheld 5/09	Teva (4/08)
Actonel	150 mg	Teva	8/12/08	9/26/08	08-cv-00627	DE	Joseph J. Farnan, Jr.	Pending	Teva (9/08), Sun (1/09, D-4/09), Apotex (3/09)
Actos	15, 30, 45 mg	Mylan	9/8/03	10/17/03	1:03-cv-08253	SD of NY	Denise L. Cote	Lost 2/06; Upheld 6/07	Mylan (10/03), Watson (10/03), Ranbaxy (10/03), Alphapharm (3/04), Sandoz (5/07), Torrent (7/09)
Actoplus Met	15/500, 15/850 mg	Mylan	6/23/08	8/5/08	1:08-cv-06999	SD of NY	Denise L. Cote	Pending	Mylan (8/08), Teva (5/09), Sandoz (6/09)
Adenoscan	3 mg/ml	Teva	4/18/05	5/26/05	1:05-cv-00337	DE	Sue L. Robinson	Settled 10/07; Launch 9/12	Teva (5/05, S-10/07), Wockhardt (9/09)
Adderall XR	5, 10, 15, 20, 25, 30 mg	Barr	NA	2/24/03	1:03-cv-01219	SD of NY	P. Kevin Castel	Settled 8/06; Launch 4/09	Barr (2/03, S-8/06), Impax (12/03, S-1/06), Colony (1/05, NS), Teva (3/05, S-3/08), Andrx (11/06, S-11/07), Sandoz (1/07, S-10/09), Actavis/Colony (3/07, S-4/08)
Advicor	20/1000 mg	Filed 5/22/08	NA	NA	NA	NA	NA	Pending	NA
Advicor	20/500 mg	Filed 9/22/08	NA	NA	NA	NA	NA	Pending	NA
Advicor	20/750 mg	Filed 12/17/08	NA	NA	NA	NA	NA	Pending	NA
Aggrenox	25/200 mg	Barr	5/31/07	7/11/07	1:07-cv-00432	DE	Gregory M. Sleet	Settled 8/08; Launch 7/15	Barr (7/07, S-8/08)
Aldara cream	5% cream	Filed 10/17/06	NA	NA	NA	NA	NA	Pending	NA
Alimta	500 mg/vial	Teva	4/24/08	6/5/08	08-cv-00335	DE	Gregory M. Sleet	Pending	Teva (6/08), APP Pharma (6/08), Barr (4/09)
Alimta	100 mg/vial	Teva	10/14/08	11/19/08	08-cv-00860	DE	Gregory M. Sleet	Pending	Teva (11/08), Barr (4/09)
Allegra tabs	30, 60, 180 mg	Barr	6/1/01	8/1/01	2:01-cv-03627 (lead case)	NJ	Joseph A. Greenaway, Jr.	At risk 9/05; Settled 11/08	Barr (9/01), Impax (3/02), Teva (2/03), Dr. Reddys (3/03), Sandoz (1/04, 8/04), Ranbaxy (4/04), Mylan (5/04, 8/05, 10/07), Wockhardt (11/07, WD-12/07), Sun (10/09)
Allegra D-12	60/120 mg	Barr	NA	1/28/02	2:01-cv-00401 (consolidated with 2:01-cv-03627)	NJ	Joseph A. Greenaway, Jr.	Settled 11/08; Launch 11/09	Barr (1/02), Impax/Teva (4/02, 3/04), Mylan (3/03, 3/04), Dr. Reddys (12/03), Sandoz (3/06, 5/07), Wockhardt (11/07, WD-12/07), Sun (1/09)
Allegra D-24	180/240 mg	Dr. Reddy's	9/14/07	10/26/07	2:07-cv-05180	NJ	Joseph A. Greenaway, Jr.	Pending	Dr. Reddy's (10/07)
Allegra tabs	30, 60, 180 mg	Dr. Reddy (505(b)2)	9/26/03	10/29/03	2:03-cv-05108	NJ	Joseph A. Greenaway, Jr.	Pending	Dr. Reddys (10/03)
Allegra D-12	60/120 mg	Dr. Reddy (505(b)2)	6/1/04	7/2/04	2:04-cv-03194	NJ	Joseph A. Greenaway, Jr.	Pending	Dr. Reddys (7/04)
Alphagan P	0.15% solution	Exela/Paddock	2/12/07	3/26/07	1:07-cv-00516	DE	Gregory M. Sleet	Lost 10/23/09	Exela (3/07), Apotex (5/07)
Alphagan P	0.10% solution	Filed 12/20/06	NA	NA	NA	NA	NA	Pending	NA
Ambien CR	12.5 mg	Anchen	NA	Not Sued	P.IV filed 1/19/06	NA	NA	NA	Anchen (1/06, NS), Actavis, Synthron (2/07), Barr (4/07), Mutual (5/07), Sandoz (3/08)
Ambien CR	6.25 mg	Actavis	NA	Not Sued	P.IV filed 2/2/06	NA	NA	NA	Actavis (2/06, NS), Anchen, Watson (1/07), Synthron (2/07), Barr (4/07), Mutual (5/07)
Amrix	15, 30 mg	Mylan	10/20/08	11/25/08	08-cv-00889	DE	Sue L. Robinson	Pending	Mylan (11/08), Barr (11/08), Impax (1/09), Anchen (7/09, 9/09)
Androgel	1%	Watson	7/8/03	8/21/03	1:03-cv-02501	ND of GA	Thomas W. Thrash Jr.	Settled 9/06; Launch 8/15	Watson (8/03, S-9/06), Paddock/Par (8/03, S-9/06)
Angeliq	0.5 mg/ 1 mg	Filed 12/26/07	NA	NA	NA	NA	NA	NA	NA
Angiomax	250 mg/vial	Teva	9/1/09	10/8/09	1:09-cv-00751	DE	Eduardo C. Robreno	NA	Teva (10/09), APP (10/09)
Antara	43mg, 130mg	Lupin	12/2/08	1/14/09	1:09-cv-00083	MD	Richard D Bennett	Dropped 10/2009	Lupin (1/09), Paddock (7/09-DJ)
Argatroban Injection	100 mg/ml	Barr	11/19/07	12/28/07	1:07-cv-11614	SD of NY	John G. Koeltl	Pending	Barr (12/07)
Aricept	5, 10 mg	Teva, Ranbaxy	10/27/05	12/7/05	2:05-cv-05727	NJ	Garrett E. Brown, Jr.	Pending	Teva (12/05), Apotex (7/09-DJ)
Aricept ODT	5, 10 mg	URL/Mutual	NA	8/3/06	2:06-cv-03613	NJ	Garrett E. Brown, Jr.	Dismissed 12/07	Mutual/URL (8/06, D-12/07)
Arthrotec	75/0.2, 50/0.2 mg	Teva	3/9/09	4/21/09	09-cv-03965	SD of NY	Richard J. Sullivan	Settled 12/09	Teva (4/09)
Asacol	400 mg	Roxane	9/14/07	10/26/07	3:07-cv-05165	NJ	Freda L. Wolfson	Pending	Roxane (10/07)
Astelirin	EQ 0.125 mg base	Apotex	1/27/05	3/10/06	1:06-cv-00164	DE	Sue L. Robinson	Settled 4/08; Launch 3/10	Apotex (3/06, 4/08-S), Sun Pharma (6/07), Cobalt (8/07, 8/08-S)
Atacand	4, 8, 16, and 32 mg	Sandoz	NA	Not Sued	NA	NA	NA	NA	Sandoz (4/07, NS), Teva (3/08, 4/08, NS), Mylan (7/08, NS)
Atacand HCT	16/12.5, 32/12.5 mg	Mylan	9/22/08	Not Sued	NA	NA	NA	NA	Mylan (9/08, NS)
Atripala	600/200/300 mg	Teva	3/30/09	5/8/09	1:08-cv-10838	SD of NY	Richard J. Sullivan	Pending	Teva (5/09)
Axid oral sol.	15 mg/ml	Filed 5/14/08	NA	NA	NA	NA	NA	Pending	NA
Avalide	150/12.5, 300/12.5 mg	Filed 11/10/04	NA	NA	NA	NA	NA	Pending	NA
Avalide	300/25 mg	Filed 6/6/06	NA	NA	NA	NA	NA	Pending	NA
Avandamet	1/500, 2/500, 4/500, 2/1000, 4/1000 mg	Teva	12/20/04	1/26/05	1:05-cv-00536	NJ	Noel L. Hillman	Settled 9/07; Launch 1Q12	Teva (1/05, S-9/07)
Avandaryl	1/4, 2/4, 4/4, 8/2, 8/4mg	Teva	3/29/07	5/11/07	1:07-cv-02238	NJ	Noel L. Hillman	Settled 9/07; Launch 1Q12	Teva (5/07, S-9/07)
Avandia	2, 4, 8 mg	Teva or Dr Reddy	7/14/03	8/26/03 (TEVA) 9/5/03 (RDY)	1:03-cv-04037 (TEVA) 1:03-cv-04179 (RDY)	NJ	Noel L. Hillman	Settled 9/07; Launch 1Q12	Teva (8/03, S-9/07), Dr. Reddys (9/03)
Avapro	75, 150, 300 mg	Teva	NA	NA	NA	NA	NA	Pending	Teva
Avelox	400 mg	Dr. Reddy's	2/10/04	3/24/04	1:04-cv-00179	DE	Sue L. Robinson	Lost 10/07	Dr. Reddy (3/04), Teva (4/07)

Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Avinza	30, 45, 60, 75, 90, 120 mg	Actavis	9/4/07	10/18/07	2:07-cv-05041	NJ	Susan D. Wigenton	Pending	Actavis (10/07), Sandoz (7/09)
Avodart	0.05 mg	Barr	1/11/08	2/25/08	1:08-cv-00112	DE	Sue L. Robinson	Pending	Barr (1/08)
Axert	6.25, 12.5 mg	Teva	2/8/06	3/24/06	1:06-cv-02293	SD of NY	Loretta A. Preska	Settled 12/07	Teva (3/06)
Azor	5/20, 10/40 mg	Mylan	4/18/08	6/3/08	2:06-cv-03462	NJ	William J. Martini	Lost 7/09	Mylan (6/08)
Benicar	5, 20, 40 mg	Mylan	6/19/06	7/31/06	2:06-cv-03462	NJ	William J. Martini	Lost 7/09	Mylan (7/06)
Benicar HCT	20/12.5, 40/12.5, 40/25 mg	Mylan	5/14/07	6/22/07	2:07-cv-03039	NJ	William J. Martini	Lost 7/09	Mylan (6/07)
Boniva	2.5 and 150 mg	Shared	7/27/07	9/7/07	2:07-cv-04284	NJ	Stanley R. Chesler	Pending	Teva (9/07), Mutual (9/07), Apotex (9/07), Dr. Reddy's (9/07), Cobalt (9/07), Orchid (9/07), Mylan (9/07), Actavis (5/08, 6/08-D)
Boniva	1 mg/ml, 3 ml vial	Filed 8/31/07	NA	NA	NA	NA	NA	NA	NA
Brovana	0.015mg base/2mL	Filed 10/1/09	NA	NA	NA	NA	NA	NA	NA
Caduet	2.5/50, 5/10, 5/20, 5/40, 10/10, 10/20, 10/80	Ranbaxy	1/24/07	3/9/07	1:07-cv-00138	DE	Joseph J. Farnan, Jr.	Lost 11/07	Ranbaxy (3/07, 3/08-DJ), Sandoz (10/09)
Candicis (inj)	50 mg/vial and 70 mg/vial	Teva	10/22/09	11/25/09	2:09-cv-06026	NJ	Stanley R. Chesler	Pending	Teva (11/09)
Carbatrol	300 mg	Nostrum Pharma	7/29/03	9/18/03	3:03-cv-04436	NJ	Mary L. Cooper	SJ denied 7/05	Nostrum (9/03), Core Pharma (5/06), Teva (5/07, S-9/09), Actavis (7/08, L-3/09)
Carbatrol	100, 200 mg	Core Pharma	3/30/06	5/17/06	2:06-cv-02266	NJ	Stanley R. Chesler	SJ granted 11/08	Core Pharma (5/06), Teva (5/07, S-9/09), Nostrum (7/08), Apotex (7/08), Actavis (7/07, L-3/09)
Cardizem LA	120, 180, 240, 300, 360, 420 mg	Andrx	6/27/2005 (420 mg) 9/2/05 (other doses)	8/10/05	1:05-cv-00586	DE	Kent A. Jordan	Settled 12/07; Launch 4/09	Andrx (8/05, 10/05, 10/06, S-12/07)
Celebrex	100, 200, 400 mg	Teva	1/6/04	2/19/04	2:04-cv-00754	NJ	John C. Lifland	Lost 3/07; Upheld in part/Reversed in part 3/08	Teva (2/04)
Celebrex	50 mg	Filed 3/21/08	NA	NA	NA	NA	NA	Pending	NA
Cenestin	1.25, 0.625mg	Paddock	1/16/09	3/2/09	1:09-cv-1905	SD of NY	NA	Pending	Paddock (3/09)
Cialis	5, 10, 20 mg	Filed 11/21/07	NA	NA	NA	NA	NA	Pending	NA
Cialis	2.5 mg	Filed 10/14/08	NA	NA	NA	NA	NA	Pending	NA
Clarinox	5 mg	Shared	8/17-8/31/06	9/29/06	3:06-cv-04715	NJ	Mary L. Cooper	Pending	Zydus, Sandoz (S-4/09), Mylan (S-4/09), Orchid (S-8/09), Perrigo (S-12/08), Glenmark, GeoPharma, Lupin (S-12/08), Ranbaxy, Sun Pharm, Watson (all 9/06), Anchen (11/07), Zydus (9/06), Dr. Reddy's (9/06, S-12/08), Orchid (S-8/09)
Clarinox RediTabs	2.5, 5 mg	Zydus, Dr. Reddy's	8/17-8/31/06	9/29/06	3:06-cv-04715	NJ	Mary L. Cooper	Settled 12/08	
Clarinox D12/24	2.5/120, 5/240 mg	Dr. Reddy's	8/17-8/31/06	9/29/06	3:06-cv-04715	NJ	Mary L. Cooper	Settled 12/08	Dr. Reddy (9/06, S-12/08), Anchen (10/07), Sandoz (3/08)
Clarinox syrup	0.5 mg/ml	Filed 5/8/08	NA	NA	NA	NA	NA	Pending	NA
Clobex lotion	0.05%	Actavis	5/22/06	7/5/06	4:06-cv-00471	ND of TX	Terry R. Means	Pending	Actavis (7/06)
Clobex shampoo	0.05%	Actavis	1/8/08	2/21/08	4:08-cv-00115	ND of TX	John McBryde	Pending	Actavis (2/08)
Clobex spray	0.05%	Paddock	11/24/08	1/7/09	4:09-cv-00002	ND of TX	Terry R. Means	Pending	Paddock (1/09); Perrigo (12/09)
Combigan	0.2%/0.5%	Sandoz	2/20/09	4/7/09	2:09-cv-00097	ED of TX	John T. Ward	Pending	Sandoz (4/09), Hi-Tech (6/09), Alcon (11/09)
Combivir	150/300 mg	Teva	9/20/07	11/2/07	1:07-cv-00713	DE	Joseph J. Farnan, Jr.	Pending	Teva (11/07), Lupin (8/08)
Comtan	200 mg	Wockhardt	8/3/07	9/13/07	1:07-cv-00550	DE	Gregory M. Sleet	Settled 4/09; Launch 9/12	Wockhardt (9/07), Sun Pharm (11/08)
Concerta	18, 27, 36, 54 mg	Impax	7/20/05	9/1/05	1:05-cv-00642	DE	Joseph J. Farnan, Jr.	Dismissed 10/06	Impax (9/05, D-10/06), Andrx (9/05)
Copaxone	20 mg/mL, 1mL	Momenta/Sandoz	7/14/08	8/28/08	1:08-cv-07611	SD of NY	Barbara S. Jones	Pending	Momenta/Sandoz (8/08), Mylan (11/09)
Cosopt	2%/0.5%	Hi-Tech Pharmcal	12/5/05	1/18/06	3:06-cv-00266	NJ	Mary L. Cooper	Lost 4/06; Upheld 4/07	Hi-Tech (1/06), Apotex (12/06)
Covera HS	240 mg	Filed 12/03	NA	NA	NA	NA	NA	Pending	NA
Coreg CR	40, 80, 10, 20 mg	URL/Mutual	12/14/07	2/4/08	2:08-cv-00549	ED of PA	Barclay Surrick	Dismissed 11/08	URL/Mutual (2/08)
Crestor	5, 10, 20, 40 mg	Shared	10/31-11/19/07	12/11/07	Multiple	DE	Joseph J. Farnan, Jr.	Pending	Aurobindo (12/07), Apotex (12/07, DJ-1/08), Cobalt (12/07), Par (12/07), Sandoz (12/07), Mylan (12/07), Sun (12/07), Teva (12/07-NS), Glenmark (12/07-NS)
Cubicin	250, 500mg/vial	Teva	2/6/09	3/23/09	09-cv-00189	DE	Gregory M. Sleet	Pending	Teva (3/09)
Cutivate	0.05%	Glenmark	10/27/08	12/12/08	08-cv-05023	ED of NY	Carol B. Amon	Pending	Glenmark (10/08), Perrigo (11/2009)
Cymbalta	20, 30, 60 mg	Shared	10/28-11/6/08	11/14/08	Multiple	SD of IN	Larry J. McKinney	Pending	Impax (11/08), Actavis (11/08), Sandoz (11/08), Wockhardt (11/08), Cobalt (11/08), Lupin (11/08), Aurobindo (11/08), Sun (12/08), Anchen (8/09)
Delsym	30mg/5mL	Tris Pharma	5/14/09	6/26/09	3:09-cv-03125	NJ	Freda L. Wolfson	Pending	Tris (6/09)
Detrol	1, 2 mg	Teva	2/23/04	3/26/04	2:04-cv-01418	NJ	Dennis M. Cavanaugh	Dismissed 3/07	Teva (3/04)
Detrol LA	2, 4 mg	Teva	10/30/07	12/12/07	2:08-cv-01331	NJ	Dennis M. Cavanaugh	Pending	Teva (12/07), Impax (3/08, 8/08)
Diastat	2.5/0.5, 5/1, 10/2, 15/3, 20/4 mg/ml	Kali/Par	5/28/04	7/8/04	2:04-cv-03238	NJ	John C. Lifland	Settled 7/07; Launch 9/10	Par (7/04, S-7/07)
Diastat acudial	5 mg/mL, 4mL	Filed 12/23/08	NA	NA	NA	NA	NA	Pending	NA
Differin	0.30%	Filed 9/15/09	NA	NA	NA	NA	NA	Pending	NA
Diovan	40, 80, 160, 320 mg	Ranbaxy	6/28/07	8/9/07	3:07-cv-03755	NJ	Mary L. Cooper	Settled 9/07; Launch 9/12	Ranbaxy (8/07, S-9/07)
Diovan HCT	80/12.5, 160/12.5, 160/25 mg	Mylan (?)	NA	NA	NA	NA	NA	Pending	NA
Diovan HCT	320/12.5, 320/25 mg	Filed 2/7/07	NA	NA	NA	NA	NA	Pending	NA
Doryx	75, 100 mg	Shared	12/23/08	2:08-cv-06304	NJ	William J. Martini	Pending	Mutual (12/08), Mylan (12/08), Impax (12/08), Sandoz (1/09), Actavis (1/09)	
Doryx	150 mg	Impax	2/1/09	3/18/09	2:09-cv-01233	NJ	William J. Martini	Pending	Impax (3/09), Mylan (5/09)
Dovonex solution	0.00005	Hi-Tech Pharmcal	NA	Not Sued	P.I.V filed 5/19/06	NA	NA	Pending	Hi-Tech (8/06, NS), Altana (9/06, NS)
Duac	1%/5%	Perrigo	4/10/09	5/28/09	09-cv-00376	DE	Sue L. Robinson	Dismissed 10/19/09	Perrigo (5/09, D-10/09)
Effexor XR caps	37.5, 75, 150 mg	Teva	2/26/03	3/24/03	2:03-cv-01293	NJ	William J. Martini	Settled 10/05; Launch 7/10	Teva (3/03, S-10/05), Impax (4/06, S-7/08), Anchen (4/06, S-11/08), Lupin (3/07, S-4/09), Osmotica (4/07, S-1/08), Sandoz (6/07), Mylan (7/07, S-12/09), Wockhardt (8/07, S-5/09), Apotex (8/08), Torrent (1/09), Zydus (4/09), Orchid (7/09)
Effexor XR tabs	37.5, 75, 150 mg	Sun Pharm	8/29/07	Convenant Not	NA	NA	NA	Pending	Sun Pharm (NS)
Elestat	0.05%	Sandoz	1/16/09	Not Sued	1:09-cv-01444	DC	NA	Pending	Sandoz (7/09-DJ)
Elocon cream	0.1%	Filed 4/03	NA	NA	NA	NA	NA	Pending	NA
Elocon lotion	0.1%	Filed 6/10/04	NA	NA	NA	NA	NA	Pending	NA

Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Eloxatin	50 mg/vial, 100 mg per vial	Shared	May 2007	June/July 2007	3:07-cv-02762	NJ	Freda L. Wolfson	Won 6/09; TRO 8/09; Remanded 9/09	Sandoz (6/07), Dabur (6/07), Par (7/07), Teva (7/07), Abraxis (7/07), Ebewe (7/07, S-7/09), Actavis (7/07), Sun/Caraco (7/07), Mayne (7/07, 9/07), Barr (1/08), Apotex (8/08)
Eloxatin	200 mg per vial	Par, Ebewe	5/24/07	7/6/07	3:07-cv-03143	NJ	Freda L. Wolfson	Pending	Par (7/07), Ebewe (7/07), Mayne (9/07), Teva (11/07), Barr (1/08)
Emend	40, 80, 125 mg	Sandoz	1/15/09	2/27/09	3:09-cv-00890	NJ	Mary L. Cooper	Pending	Sandoz (2/09)
Enablex	7.5, 15 mg	Teva, Watson, Anchen	3/19/09	4/24/09	1:09-cv-00291	DE	Sue L. Robinson	Pending	Teva (4/09), Watson (4/09), Anchen (4/09)
Entocort	3 mg	Barr	4/9/08	5/22/08	1:08-cv-00305	DE	Gregory M. Sleet	Pending	Barr (5/08), Mylan (7/08)
Epipen	0.15, 0.3 mg	Teva	7/20/09		1:09-cv-00652	DE	Gregory M. Sleet	Pending	Teva (9/09)
Epivir	150 mg	Filed 10/1/07		NA	NA	NA	NA	NA	NA
Epivir HBV	100 mg	Filed 10/31/07		NA	NA	NA	NA	NA	NA
Epzicom	600/300 mg	Aurobindo (?)	NA	NA	NA	NA	NA	NA	NA
Equetro	200, 300 mg	Actavis (?)	12/4/07	1/17/08	1:08-cv-00036	DE	Gregory M. Sleet	Pending	Actavis (1/08)
Ethylol	500 mg/vial	Sun Pharm	6/29/04	8/12/04	1:04-cv-02612	MD	Marvin J. Garbis	At risk 3/08; Settled 7/09	Sun Pharm (8/04)
Evista	60 mg	Barr	10/9/02	11/26/02	1:02-cv-01844	SD of IN	Sarah Evans Barker	Lost 9/09	Barr (12/02), Teva (6/06), Invagen (1/09)
Evoclin	1%	Perrigo/Cobrek	1/29/09	3/13/09	1:09-cv-00167	DE	Sue L. Robinson	Pending	Cobrek (3/09)
Evoxac	30mg	Apotex	NA	6/26/09	1:09-cv-00470	DE	Jerome B. Simandle	Pending	Apotex (6/09), Sandoz (11/09)
Exforge	10/160 mg	Par	NA	Not Sued	NA	NA	NA	NA	Par (10/07, NS)
Exforge	5/160 mg	Par	NA	Not Sued	NA	NA	NA	NA	Par (10/07, NS)
Exforge	10/320 mg	Par	NA	Not Sued	NA	NA	NA	NA	Par (11/07, NS)
Exforge	5/320 mg	Par	NA	Not Sued	NA	NA	NA	NA	Par (11/07, NS)
Exelon caps	1.5, 3, 4.5, 6 mg	Dr. Reddy's, Sun Pharm	NA	8/5/04	1:04-cv-06045	SD of NY	Harold Baer	Settled 12/07, 1/08	Dr. Reddys (8/04, S-1/08), Sun Pharm (8/04, S-12/07), Ranbaxy (3/05), Watson (5/05, D-12/07)
Exelon solution	2 mg/ml	Ranbaxy	NA	NA	NA	NA	NA	Pending	Ranbaxy
Factive	320 mg	Orchid	5/30/08	NA	NA	NA	NA	Pending	Orchid
Famvir	125, 250, 500 mg	Teva	2/22/05	4/8/05	2:05-cv-01887	NJ	Dennis M. Cavanaugh	At risk 9/07; Lost 11/09	Teva (4/05), Roxane (3/08)
Faslodex (inj)	50 mg/mL, 2.5 mL, 5 mL	Filed 10/1/09	NA	NA	NA	NA	NA	NA	NA
Fazaclor	25, 100 mg	Barr	7/14/08	8/21/08	1:08-cv-00531	DE	Joseph J. Farnan, Jr.	Case closed 8/09	Barr (8/08), Novel (11/08)
Femara	2.5 mg	Mylan	5/10/06	6/26/06	3:06-cv-02885	NJ	Mary L. Cooper	Settled 12/08	Mylan (6/06)
Femcon Fe	0.035 mg; 0.04 mg	Barr	8/13/07	9/24/07	2:07-cv-04560	NJ	William J. Martini	Settled 12/08	Barr (9/07, S-12/08), Watson (9/07, S-1/09), Lupin (8/09)
Fentora	.1, .2, .3, .4, .6, .8 mg	Watson	4/21/08	6/2/08	3:08-cv-00330	DE	Sue L. Robinson	Pending	Watson (6/08), Barr (7/08, 10/08, S-11/09)
Flomax	0.4 mg	Ranbaxy	4/6/05	5/13/05	3:05-cv-02563	NJ	Mary L. Cooper	Lost 2/07; Settled 11/07	Ranbaxy (5/05, S-11/07), Impax (7/08; s-10/09)
			7/9/04 (5, 10 mg)						
			7/28/04 (2.5 mg)						
Focalin daily	2.5, 5, 10 mg	Teva	8/19/04	8/19/04	3:04-cv-04030	NJ	Freda L. Wolfson	Pending	Teva (8/04), Par (10/07)
Focalin XR	5, 10, 20 mg	Teva	8/3/07	9/14/07	1:07-cv-00552	DE	Sue L. Robinson	Pending	Teva (9/07), Par (10/07), Actavis (10/07), Barr (11/07)
Focalin XR	15 mg	Par	8/23/07	10/4/07	1:07-cv-00603	DE	Sue L. Robinson	Pending	Par (10/07), Actavis (10/07), Barr (11/07)
Fortamet	500, 1000 mg	Lupin	12/3/08	1/15/09	09-cv-00037	DE	Joseph J. Farnan, Jr.	Pending	Lupin (1/09)
Fortical	200 mcg	Apotex	6/12/06	7/24/06	1:06-cv-05571	SD of NY	Robert P. Patterson	Pending	Apotex (7/06)
Fosrenol	500, 750, 1000 mg	Mylan, Barr, Natco	3/2/09	3/16/09	1:09cv02380	SD of NY	Paul G. Gardephe	Pending	Mylan (3/09), Barr (3/09), Natco (3/09)
Gabitril	2, 4 mg	Sun Pharm	NA	Not Sued	P. IV filed 2/1/05	NA	NA	Pending	Sun (5/05)
Gemzar	200 mg/vial	Teva	1/4/06	2/15/06	1:06-cv-00238	SD of IN	Sarah Evans Barker	Won 8/09	Teva (2/06), Mayne (8/06), Sun Pharm (12/06, D-9/07), Sandoz (10/09)
Gemzar	1 g/vial	Teva	1/17/06	2/15/06	1:06-cv-00238	SD of IN	Sarah Evans Barker	Won 8/09	Teva (2/06), Sun Pharm (12/06, D-9/07), Sandoz (10/09)
Gemzar	2 g/vial	Hospira/Mayne	12/5/07	1/10/08	1:08-cv-00037	SD of IN	Sarah Evans Barker	Won 8/09	Hospira (1/08), Mayne (1/08), Teva, (9/08)
Geodon	20, 40, 60, 80 mg	Lupin	NA	NA	NA	NA	NA	Pending	Lupin
Gleevec	100, 400 mg	Sun Pharm	NA	NA	NA	NA	NA	Pending	NA
Glumetza	500, 1000 mg	Lupin	11/6/09	11/25/09	09-cv-05587	ND of CA	NA	Pending	NA
Hectorol (inj)	2 mcg/ml, 2 ml ampules	Perrigo/Pentech	NA	2/21/08	1:08-cv-01083	ND of IL	Robert M. Dow, Jr	Pending	Pentech (2/08), Eagle (4/09), Sandoz (7/09), Roxane (8/09)
Integrelin	2 mg/mL, 10 mL vial	Teva	1/8/09	2/18/09	09-cv-00105	DE	J. Curtis Joyner	NA	Teva (2/09)
Kaletra	100/25, 200/50 mg	Mylan	1/30/09	3/13/09	1:09-cv-01586	ND of IL	Robert M. Dow, Jr.	Pending	Mylan (3/09)
Lescol XL	80 mg	Par	NA	Not Sued	NA	NA	NA	Pending	Par (3/07, NS)
Lescol	20, 40 mg base	Mylan	8/27/08	10/10/08	2:08-cv-05042	NJ	Peter G. Sheridan	Pending	Mylan (10/08)
Lexapro	5, 10, 20 mg	Ivax	NA	9/23/03	1:03-cv-00891	DE	Joseph J. Farnan Jr.	Lost 7/06; Upheld 9/07	IVAX (9/03), Alphapharm (5/04, S-10/05), Caraco (7/06, S-7/09)
Levitra	5, 10, 20 mg	Teva	5/19/09	7/1/09	1:09-cv-00480	DE	Gregory M. Sleet	Pending	Teva (7/09)
									Ranbaxy (2/03, DJ-3/08), Teva (6/07, 4/08), Cobalt (10/07), Apotex (12/08), Mylan (6/09), KUDCO (11/09), Kremers-Urban (12/09), Dr. Reddys (12/09)
Lipitor	10, 20, 40, 80 mg	Ranbaxy	1/10/03	2/25/03	1:03-cv-00209	DE	Joseph J. Farnan Jr.	Lost 12/05; Upheld 8/06	Watson (7/06, S-1/09), Lupin (8/09, D-10/09)
Loestrin 24 Fe	1 mg/0.02 mg and 75 mg	Watson	6/19/06	7/28/06	2:06-cv-03491	NJ	Harold A. Ackerman	Settled 1/09	Paddock (6/06, S-8/07), Glenmark (10/09, S-11/09)
Loprox gel	0.77% gel	Paddock	5/8/06	6/22/06	0:06-cv-02588	MN	Michael J Davis	Settled 8/07	Teva (9/04), Watson (3/06), Par (10/06, S-2/09), Lupin (12/06, S-9/09), Dr Reddy (7/07, 5/08, S-9/09), Mylan (10/07), Cobalt (12/08, S-9/09)
Lotrel	2.5/10, 5/10, 5/20, 10/20 mg	Teva	8/6/04	9/16/04	2:04-cv-04473	NJ	Garrett E. Brown, Jr.	At risk 5/07; PI denied 6/07	Par (12/06), Lupin (12/06, S-9/09), Teva (2/08), Cobalt (6/08)
Lotrel	5/40, 10/40 mg	Par	11/17/06	12/29/06	2:06-cv-04788	NJ	Garrett E. Brown, Jr.	Pending	Teva (4/09), Par (4/09), Apotex (4/09)
Lovaza	1g	Par, Teva, Apotex	3/17/09	4/23/09	1:09-cv-00286	DE	Sue L. Robinson	Pending	
									Won SJ 6/05; Overtured 4/06 (Remanded); Won 2/07; Under appeal
Lovenox	Multiple	Amphastar Pharma	NA	8/4/03	5:03-cv-00887	CD of CA	Mariana R. Pfaelzer		Amphastar (8/03), Teva, Momenta/Sandoz, Eon (8/06), Hospira (12/07)



Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Lumigan	0.03%	Barr	3/26/09	5/7/09	09-cv-00333	DE	Sue L. Robinson	Pending	Barr (5/09)
Lunesta	1, 2, 3 mg	Shared	Multiple	3/20/09	2:09-cv-01302	NJ	Dennis M. Cavanaugh	Pending	Teva (3/09), Wockhardt (3/09), Reddy's (3/09), Roxane (3/09), Cobalt (3/09), Glenmark (3/09), Orchid (3/09), Orgenus (3/09), Lupin (3/09), Sun Pharm (3/09),
Luvox CR	100, 150 mg	Actavis, Anchen	8/24/09	10/6/09	1-09-cv-00744	DE	Gregory M. Sleet	Pending	Actavis (10/09), Anchen (10/09)
Luxiq	0.12%	Perrigo/Pentech	9/24/07	11/6/07	1:07-cv-06297	ND of IL	Joan B. Gottschall	Pending	Pentech (11/07)
Lybrel	0.02 mg/0.09 mg	Watson	2/1/08	3/12/08	1:08-cv-00145	DE	Joseph J. Farnan, Jr.	Dismissed 4/09; Launch 5/10	Watson (3/08, D-4/09), Sandoz (5/08, D-9/09)
Lyrica	25, 50, 75, 100, 150, 200, 225, 300mg	Shared	3/17/09	4/29/09	Multiple	DE	Gregory M. Sleet	Pending	Teva (4/09), Mylan (4/09), Lupin (4/09), Sandoz (4/09), Actavis (4/09), Wockhardt (4/09), Sun (4/09), Cobalt (4/09),
Malarone	250/100mg	Glenmark	8/10/09	8/14/09	1:09-cv-00608	DE	Joseph J. Farnan, Jr.	Pending	Glenmark (8/09)
Maxalt	5, 10 mg	Filed 9/2/04	NA	NA	NA	NA	NA	Pending	NA
Maxalt MLT	5, 10 mg	Mylan (?)	NA	NA	NA	NA	NA	Pending	NA
Meridia	10, 15 mg	Apotex	11/9/09	12/23/09	1:09-cv-07968	ND of IL	Rebecca R. Pallmeyer	Pending	NA
Metadate CD	10, 20, 30 mg	Filed 5/13/05	NA	NA	NA	NA	NA	Pending	NA
Metadate CD	40 mg	KV Pharm	NA	4/18/08	1:08-cv-00223	DE	Joseph J. Farnan, Jr.	Pending	KV (4/08)
Metrogel (topical)	0.75%	Tolmar	1/19/09	3/3/09	3:09-cv-0400	ND of TX	David C. Godbey	Dismissed 4/09	Tolbar (3/09, D-4/09)
Micardis	20, 40, 80 mg	Watson (?)	NA	NA	NA	NA	NA	Pending	NA
Micardis HCT	80/12.5, 80/25mg	Filed 12/31/08	NA	NA	NA	NA	NA	Pending	NA
Mirapex	0.25, 0.125, 0.5, 1.0, 1.5 mg	Barr	8/10/05	9/26/05	1:05-cv-00700	DE	Joseph J. Farnan, Jr.	Won 6/08; Settled 8/08; Launch 1/10	Barr (9/05, S-8/08), Mylan (12/05)
Monistat 1									
Combination Pack	2% and 1.2 g	Perrigo	3/7/08	4/18/08	3:08-cv-01909	NJ	Freda L. Wolfson	Dismissed 9/08	Perrigo (4/08)
Moviprep oral soln	100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch	Novel Labs	NA	5/14/08	3:08-cv-02311	NJ	Freda L. Wolfson	Pending	Novel (5/08)
Mucinex SE	600, 1200 mg	URL/Mutual	8/22/06	10/2/06	2:06-cv-04418	ED of PA	Paul S. Diamond	Settled 3/07; Launch 7/12	Mutual/URL (10/06, S-3/07), Perrigo (9/07), Watson (4/09)
Mucinex DM	600/30, 1200/60 mg	Watson	3/11/09	4/24/09	1:09-cv-03933	SD of NY	Barbara S. Jones	Pending	Watson (4/09)
Mucinex D	600/60, 1200/120 mg	Watson	4/21/09	6/5/09	1:09-cv-04455	SD of NY	Barbara S. Jones	Pending	Watson (6/09)
Myfortic	180, 360 mg	Apotex	9/20/09	11/4/09	1:09-cv-06950	ND of IL	David H. Coar	Pending	Apotex (11/09)
Namenda	5, 10 mg	Shared	Multiple	1/10/08	1:08-cv-00021	DE	Multiple	Pending	Barr (1/08, WD-5/09), Cobalt (1/08, S-10/09), Lupin (1/08, S-12/09), Orchid (1/08), Teva (1/08, S-11/09), Upsher-Smith (1/08, S-9/09), Wockhardt (1/08, S-9/09), Dr. Reddy's (1/08, WD-12/09), Mylan (1/08), Amneal (1/08, S-9/09), Genpharm (1/08, WD-10/09),
Namenda	15, 20 mg	Upsher-Smith	12/14/07	1/10/08	1:08-cv-00021	DE	Gregory M. Sleet	Pending	Upsher-Smith (1/08)
Nasacort AQ	0.055 mg/spray	Barr/Perrigo	3/20/06	5/2/06	1:06-cv-00286	DE	Gregory M. Sleet	Settled 11/08; Launch 6/11	Barr (5/06)
Nasonex	50mcg spray	Apotex	NA	12/18/09	3:09-cv-06373	NJ	Garrett E. Brown, Jr.	Pending	Apotex (12/09)
Nexium	20, 40 mg	Ranbaxy	10/14/05	11/21/05	3:05-cv-05553	NJ	Garrett E. Brown, Jr.	Settled 4/05; Launch 5/27/14	Ranbaxy (11/05), Ivax (3/06, 10/08), Dr. Reddy's (7/07), Mylan (NS), Sandoz
Nexium (inj)	20, 40 mg/vial	Teva	NA	4/25/08	08-cv-00238	NJ	Joel A. Pisano	Pending	Teva (4/08)
Niaspan	1000 mg	Barr	NA	3/4/02	1:02-cv-01683	SD of NY	Victor Marrero	Settled 4/05; Launch 9/13	Barr (3/02, S-4/05), Lupin (3/09)
Niaspan	500, 750 mg	Barr	NA	8/12/02	1:02-cv-08995	SD of NY	Victor Marrero	Settled 4/05; Launch 9/13	Barr (3/02, S-4/05), Lupin (3/09)
Nimbex (inj)	2mg/mL, 5mL vial, 10 mg/mL, 20mL vial, 2mg/mL, 10 mL vial	Sandoz	11/6/09	12/18/09	1:09-cv-00972	DE	Gregory M. Sleet	Pending	Sandoz (12/09)
Niravam	0.25, 0.5, 1.0, 2 mg	Par	3/17/06	4/28/06	2:06-cv-01970	NJ	Dickinson R. Debevoise	At risk 1/09	Par (4/06), Actavis (2/07)
Nitrostat	0.3, 0.4, 0.6 mg	Filed 10/19/05	NA	NA	NA	NA	NA	Pending	NA
Nuvigil	100, 200mg (amend: 50, 150, 250mg)	Teva	10/19/09	12/2/09	1:09-cv-00918	DE	Gregory M. Sleet	Pending	Teva (12/2/09), Actavis (12/8/09), Mylan (12/11/09), Watson (1/10)
Nuvigil	200mg)	Mylan	11/2/09	12/11/09	1:09-cv-00954	DE	Gregory M. Sleet	Pending	Teva (12/2/09), Actavis (12/8/09), Mylan (12/11/09), Watson (1/10)
Olux	0.05% foam	Perrigo	9/7/05	10/19/05	2:05-cv-05038	NJ	Garrett E. Brown, Jr.	PI Denied, Launched 3/08	Perrigo (10/05), Pentech (4/08)
Opana ER	5, 10, 20, 40 mg	Impax	10/3/07	11/15/07	2:09-cv-00831	NJ	Katharine S. Hayden	Pending	Impax (11/07), Actavis (3/08-S 2/09), Sandoz (8/08), Barr (10/08)
Opana ER	30 mg	Actavis	6/30/08	7/11/08	2:08-cv-01563	NJ	Katharine S. Hayden	Pending	Actavis (7/08-S 2/09), Impax (7/08), Teva (7/09)
Opana ER	7.5, 15mg	Actavis	5/29/08	7/11/08	2:08-cv-01563	NJ	Katharine S. Hayden	Pending	Actavis (7/08-S 2/09), Impax (7/08), Teva (7/09)
Optivar	0.05% solution	Apotex	3/6/07	4/17/07	1:07-cv-00204	DE	Sue L. Robinson	Settled 4/08; Launch 12/09	Apotex (3/07), Sun Pharm (6/07)
Oracea	40 mg	Mylan	2/4/09	3/19/09	1:09-cv-00184	DE	Joseph J. Farnan, Jr.	Pending	Mylan (3/09), Lupin (7/09), Impax (9/09)
Ortho Evra	0.15 mg/0.02 mg	Filed 3/22/07	NA	NA	NA	NA	NA	Pending	NA
Ortho Tri-Cyclen Lo	0.18/0.025, 0.215/0.025, 0.25/0.025 mg/mg	Barr	8/20/03	10/1/03	2:03-cv-04678	NJ	Stanley R. Chesler	At Risk 6/09; Settled 7/09; Launch 12/15	Barr (10/03, S-7/09), Watson (10/08), Sandoz (6/09)
Osmoprep	1.102 g and 0.398 g	Novel Labs	7/25/08	9/8/08	3:08-cv-04628	NJ	Freda L. Wolfson	Pending	Novel (9/08)
Oxytrol	3.9mg/24hrs	Barr	9/11/08	10/23/08	1:08-cv-00793	DE	Gregory M. Sleet	Settled 10/09; Launch 4/15	Barr (10/08, S-10/09)
Patanol	0.1%	Apotex	10/12/06	11/15/06	1:06-cv-01642	SD of IL	Richard L. Young	Pending	Apotex (11/06), Barr (10/07), Sandoz (2/09)
Pataday	0.2%	Barr	11/24/08	1/8/09	1:09-cv-00026	SD of IN	Jane Magnus-Stinson	Pending	Barr (1/09), Apotex (2/09)
Paxil CR	37.5 mg	Filed 5/19/09	NA	NA	NA	NA	NA	Pending	NA
Perforomist	0.2mg/2mL	Teva	5/12/09	6/23/09	1:09-cv-00087	ND of WV	Irene M. Keeley	Pending	Teva (6/09)
Plavix	75 mg	Apotex	3/14/02	3/21/02	2:02-cv-02255	SD of NY	Sidney H. Stein	Settled 3/06 (Rejected 7/06); Lost 6/07	Apotex (3/02, S-3/06), Dr. Reddy (5/02), Teva (9/04), Watson (8/04, S-8/09)), Mylan, Sandoz, Cobalt (9/05), Sun (7/08)
Prandimet	1/500, 2/500 mg	Apotex	9/10/09	10/22/09	1:09-cv-08939	SD of NY	Paul G. Gardephe	Pending	Actavis (10/09), Sandoz (11/09)
Prandin	0.5, 1.0, 2 mg	Caraco	4/26/05	6/9/05	4:05-cv-40188	ED of MI	Donald A. Scheer	Lost 6/22/09	Caraco (6/05), Mylan (5/09)
Precedex	100mcg/mL	Sandoz	7/27/09	9/4/09	3:09-cv-04591	NJ	Mary L. Cooper	Pending	Sandoz (9/09)
Prevacid	15, 30 mg	Teva	12/5/05	1/17/06	1:06-cv-00033	DE	Sue L. Robinson	Lost 3/31/08	Teva (1/06)
Prevacid SoluTabs	15, 30 mg	Teva	4/12/07	5/25/07	1:07-cv-00331	DE	Sue L. Robinson	Won 11/09	Teva (5/06), Barr (6/08)
Primaxin IM	500, 750 mg	Ranbaxy	1/22/07	4/30/07	1:07-cv-00229	DE	Gregory M. Sleet	Dismissed 7/08	Ranbaxy (4/07)

Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Protonix	20, 40 mg	Teva, Sun Pharm	4/6/04	5/20/04	2:04-cv-02355	NJ	Jose L. Linares	At risk 12/07	Teva (4/04), Sandoz (4/04-PII on compound patent, PIV on formulation patents), SunPharm (4/04, 5/05), KUDCO (8/06), Apotex (8/09)
Protonix IV	40 mg/vial	Sun Pharm	3/1/05	5/5/05	2:05-cv-02391	NJ	Jose L. Linares	Pending	Sun Pharm (6/05), Teva (NS), Apotex (2/08), Sandoz (5/08), Teva (6/08)
Provigil	100, 200 mg	Teva, Mylan, Barr, Ranbaxy	3/28/03	3/31/03	2:03-cv-01394	NJ	John C. Lifland	Settled 12/05, 1/06, 2/06; Launch 4/12	Teva (3/03-S), Mylan (3/03-S), Ranbaxy (3/03-S), Barr (3/03-S), Sandoz (5/04-DR 5/05), Carlsbad (2/05-S), Caraco (11/05-NS), Apotex (1/06-NS), Hikma (8/08-NS)
Pulmicort Respules	0.25/2 ml, 0.5/2 ml	Ivax	9/14/05	10/26/05	1:05-cv-05142	NJ	Renee Marie Bumb	Settled 11/08	Ivax (10/05), Breath (3/08), Apotex (4/09)
Quixin	0.5% solution	Hi-Tech Pharmacal	11/7/03	12/19/03	1:03-cv-01151	DE	Kent A. Jordan	Dismissed 2/04	Hi-Tech (10/03)
Reclast (inj)	0.05 mg/mL, 100 mL vial	Teva	11/7/08	12/18/08	08-cv-00952	DE	Sue L. Robinson	NA	Teva (12/08)
Renagel	400, 800 mg	Mylan (?)	NA	Not Sued	NA	NA	NA	Pending	Mylan ? (Not Sued), Lupin (3/09), Impax (3/09), Sandoz (7/09), Endo (10/09)
Renvela	800 mg	Impax	2/23/09	4/3/09	1:09-cv-00846	MD	J. Frederick Motz	Pending	Impax (4/09), Lupin (5/09)
Requip XL	2, 3, 4, 8, 12 mg	Impax, Actavis	Jan 2009	Not Sued	NA	NA	NA	Pending	NA
Reyataz	100, 150, 200, 300 mg	Teva	10/19/09	12/2/09	1:09-cv-00919	DE	Sue L. Robinson	Pending	NA
Rhinocort spray	0.032 mg (32 mcg)/spray	Apotex	Not Sued	Not Sued	NA	NA	NA	Not sued	NA
Ritalin LA	20, 30, 40 mg	Abrika	10/23/06	12/6/06	2:06-cv-05818	NJ	Freda L. Wolfson	Pending	Abrika (12/06), KV (10/07), Barr (10/07)
Ritalin LA	10 mg	Filed 5/21/07	NA	NA	NA	NA	NA	Pending	KV (10/07), Barr (10/07)
Rogaine Foam	5%	Perrigo	8/26/09	10/9/09	1:09-cv-00758	DE	Gregory M. Sleet	Pending	Perrigo (10/09)
Rozereem	8 mg	Teva	7/22/09	11/6/09	1:09-cv-00841	DE	Sue L. Robinson	Pending	Teva (11/09), Watson (12/09)
Rythmol SR	225, 325, 425 mg	Par	11/8/06	12/19/06	1:06-cv-00774	DE	Joseph J. Farnan, Jr.	Settled 4/09	Par (12/06, S-4/09)
Ryzolt	100, 200, 300 mg	Sun	9/29/09	11/5/09	1:09-cv-00833	DE	Kent A. Jordan	Pending	Sun (11/09)
Sanctura XR	60 mg	Watson	6/2/09	7/13/09	09-cv-00511	DE	NA	Pending	Watson (7/09); Sandoz (11/09)
Sandostatin	Multiple	Sun Pharm (?)	NA	NA	NA	NA	NA	Pending	KV (10/07), Barr (10/07)
Seasonale	0.03 mg; 0.15 mg	Watson	NA	12/13/07	3:07-cv-05941	NJ	Mary L. Cooper	Pending	Watson (12/07), Sandoz (12/07), Lupin (9/09)
Seasonique	0.03 mg; 0.15 mg	Watson	1/22/08	3/6/08	2:08-cv-01145	NJ	Jose L. Linares	Dismissed 3/08	Watson (3/08, D-3/08)
Sensipar	30, 60, 90 mg	Barr, Teva	6/12/08	7/25/08	1:08-cv-00464	DE	Harvey Bartle, III	Pending	Barr (7/08), Teva (7/08)
Seroquel	25, 50, 100, 150, 200, 300, 400 mg	Teva	9/26/2005 (25 mg) 2/21/06 (100, 200, 300 mg)	11/8/2005 (25 mg) 3/31/06 (100, 200, 300 mg)	3:05-cv-05333 (25 mg) 2:06-cv-01528 (100, 200, 300 mg)	NJ	Joel A. Pisano	Lost SJ 7/08; Upheld 9/09	Teva (11/05, 25 mg, 3/06, 100, 200, 300 mg, 7/07, 50, 150, 400 mg), Sandoz (4/07)
Seroquel XR	150, 200, 300, 400 mg	Handa Pharmaceuticals	7/23/08 (400 mg)	7/28/08	3:08-cv-03773	NJ	Joel A. Pisano	Pending	Handa (7/08, 10/08), Accord/Intas (9/08), Biovail (1/09)
Simcor	20/1000 mg	Filed 9/17/09	NA	NA	NA	NA	NA	Pending	NA
Singulair tablets	4, 5, 10 mg	Teva	2/23/07	4/3/07	3:07-cv-01596	NJ	Garrett E. Brown, Jr.	Lost 8/09	Teva (4/07)
Singulair chewables	4, 5 mg	Teva	4/4/07	5/14/07	3:07-cv-02264	NJ	Garrett E. Brown, Jr.	Lost 8/09	Teva (5/07)
Singulair granules	4 mg	Teva	12/8/08	1/16/09	09-cv-00233	NJ	Garrett E. Brown, Jr.	Lost 8/09	Teva (1/09)
Skelaxin	800 mg	Eon	11/3/04	12/17/04	1:04-cv-05540	ED of NY	David. G. Trager	Won SJ 1/09	Eon (12/04)
Solaraze	3% topical	Novartis Consumer (505b2)	3/20/07	5/3/07	2:07-cv-02075	NJ	Dennis M. Cavanaugh	Pending	Novartis (5/07)
Solodyn	45, 90, 135 mg	Impax	1/15/08	1/15/08	3:08-cv-00253	ND of CA	Maxine M. Chesney	Dismissed 4/08;	Impax (1/08, S-12/08)
Solodyn	45, 90, 135 mg	Mylan, Barr, Sandoz	12/8/08	1/13/09	1:09-cv-00033	DE	Joseph J. Farnan, Jr.	Pending	Mylan (1/09), Sandoz (1/09, S-8/09), Barr (1/09, S-3/09), Ranbaxy (6/09), Lupin (11/09)
Solodyn	65, 115 mg	Teva	11/20/09	12/28/09	1:09-cv-03464	MD	Marvin J. Garbis	Pending	Teva (12/09), Lupin (1/10)
Stalevo 100, 150	25/100/200, 37.5/150/200 mg	Sun Pharm	10/1/07	11/13/07	3:07-cv-05436	NJ	Mary L. Cooper	Pending	Sun (11/07)
Stalevo 50, 200	12.5, 50, 200 mg	Wockhardt	10/29/08	12/8/08	08-cv-00917	DE	Gregory M. Sleet	Settled 4/09; Launch 9/12	Wockhardt (12/08)
Stalevo 75, 125	18.75 mg/75 mg/200 mg and	Filed 5/19/09	NA	NA	NA	NA	NA	Pending	NA
Starlix	60, 120 mg	Par, Teva, Watson	1/19/05	Not Sued	NA	NA	NA	Pending	Par (NS), Teva (NS), Watson (NS)
Strattera	10, 18, 25, 40, 60, 80, 100 mg	Shared	6/28-8/16/07	8/9-9/5/2007	2:07-cv-03770	NJ	Dennis M. Cavanaugh	Pending	Actavis (8/07), Sandoz (8/07-DJ, 9/07), Sun (9/07), Glenmark (9/07, 7/08-S), Mylan (9/07), Teva (9/07), Apotex (9/07), Aurobindo (9/07), Synthron (9/07, 8/08-
Sular	25.5, 34 mg	Filed 11/28/08	NA	NA	NA	NA	NA	Pending	NA
Suprane	99.9%	Minrad	12/12/08	1/23/09	09-cv-00054	DE	Unassigned	Pending	Minrad (1/09)
Sustiva	600 mg	Mylan	7/16/09	8/28/09	09-cv-00651	DE	Unassigned	Pending	NA
Symbyax	6/25, 12/25, 6/50, 12/50 mg	Teva	3/11/05	4/22/05	1:05-cv-00595	SD of IN	Richard L. Young	Dismissed 10/07	Teva (4/05)
Tarceva	25, 100, 150 mg base	Teva, Mylan	2/6/09	3/19/09	1:09-cv-00185 2:07-cv-05855	DE	Sue L. Robinson	Pending	Teva (3/09), Mylan (3/09)
Tarka	4/240, 2/240, 2/180, 1/240 mg	Glenmark	10/29/07	12/7/07	2:08-cv-01658 (1 mg/240 mg dose)	NJ	Dennis M. Cavanaugh	Pending	Glenmark (12/07, 4/08 for 1 mg/240 mg)
Tarka	1/240 mg	Filed 2/20/08	NA	NA	NA	NA	NA	Pending	NA
Taxotere	20/2, 80/8, 160mg/16ml	Hospira 505b2	9/28/07	11/9/07	1:07-cv-00721	DE	Gregory M. Sleet	Pending	Hospira b2 (11/07), Apotex b2 (8/08); Sun b2 (8/09)
Taxotere	40/1, 20/0.5, 80mg/2ml	Apotex 505b2	6/27/08	8/8/08	1:08-cv-00496	DE	Gregory M. Sleet	Pending	Hospira b2 (11/07), Apotex b2 (8/08); Sun b2 (8/09)
Taxotere	40 mg/mL, 0.5 mL and 2 mL	Sandoz	9/15/09	10/29/09	1:09-cv-00810	DE	Pending	Pending	Sandoz (10/09)
Temodar	5, 20, 100, 250 mg	Barr	6/8/07	7/20/07	1:07-cv-00457	DE	Sue L. Robinson	Pending	Barr (7/07)
Temodar	140, 180 mg	Filed 3/24/08	NA	NA	NA	NA	NA	Pending	NA
Testim	1%	Upsher-Smith	10/22/08	12/4/08	1:08-cv-00908	DE	Sue L. Robinson	Pending	Upsher-Smith (12/08)
Thalomid	50, 100, 150, 200 mg/vial	Barr	12/6/06	1/18/07	2:07-cv-00286 (lead case)	NJ	Susan D. Wigenton	Pending	Barr (1/07, 8/07 on new '012 patent, 11/07 on 150 mg dose)
Tobi	300mg/5ml	Teva	10/27/09	12/10/09	1:09-cv-00949	DE	Noel L. Hillman	Pending	Teva (12/09)
Travatan	0.004%	Teva	3/17/09	4/30/09	1:09-cv-00318	DE	Legrome D. Davis	Pending	Teva (4/09), Par (7/09), Apotex (10/09)
Travatan Z	0.004%	Par	6/1/09	7/1/09	1:09-cv-00481	DE	Legrome D. Davis	Pending	Par (7/09), Teva (7/09)

Drug	Dose	Estimated First Filer	Date Notified	Date Sued	Case Number	Court	Judge	Outcome for Generic	Other Paragraph IV Filers (Date Sued)
Tricor tab	160 mg	Teva	NA	10/4/02	1:02-cv-01512	DE	Kent A. Jordan	Settled 6/05	Teva (11/02, S-6/05), Impax (1/03), Par (2/03), Ranbaxy (1/04)
Tricor tab	54 mg	Teva	NA	10/4/02	1:02-cv-01512	DE	Kent A. Jordan	Settled 6/05	Teva (11/02, S-6/05), Impax (1/03), Par (2/03), Ranbaxy (1/04)
Tricor tab	145 mg	Teva	1/16/08	2/29/08	2:08-cv-01085	NJ	Joseph A. Greenaway, Jr.	Settled 11/09	Teva (2/08, S-11/09), Biovail (11/08), Lupin (3/09), Impax (10/09)
Tricor tab	48 mg	Biovail	9/19/08	11/3/08	1:08-cv-06274	ND of IL	Wayne R. Andersen	Pending	Biovail (11/08), Lupin (3/09), Impax (10/09)
Treximet	85/500 mg	Par	10/8/08	11/14/08	6:08-cv-00437	ED of TX	Leonard Davis	Pending	Par (11/08), Mylan (1/09), Teva (4/09), Dr. Reddy's (9/09)
Truvada	200/300 mg	Teva	11/3/08	12/12/08	1:08-cv-10838	SD of NY	Richard J. Sullivan	Pending	Teva (12/08)
Tygacil (inj)	50mg/vial	Sandoz	10/30/09	12/11/09	1:09-cv-00955	DE	Joseph J. Farnan, Jr.	Pending	Sandoz (12/09)
Uroxatral	10 mg	Shared	Multiple	9/21/07	1:07-cv-00572	DE	Gregory M. Sleet	Pending	Actavis/Par (9/07), Aurobindo (9/07), Mylan (9/07), Teva (9/07), Sun (9/07), Torrent (9/07), Ranbaxy (9/07), Barr (9/07), Apotex (12/07), Wockhardt (3/08)
Valcyte	450 mg	Ranbaxy	3/17/05	4/28/06	3:06-cv-02003	NJ	Freda L. Wolfson	Won 9/09	Ranbaxy (4/06)
Valtrex	500, 1000 mg	Ranbaxy	4/1/03	5/9/03	3:03-cv-02158	NJ	Mary L. Cooper	Settled 7/07	Ranbaxy (5/03, S-7/07), Apotex (7/09-DJ)
Vanos	0.1% cream	Perrigo	4/25/08	6/6/08	1:08-cv-00539	WD of MI	Paul L. Maloney	Settled 4/09	Perrigo (6/08, S-4/09), Glenmark (6/09, S-11/09)
Velcade	3.5mg/vial	Teva	1/16/09	2/27/09	1:09-cv-00127	DE	Gregory M. Sleet	Pending	Teva (2/09)
Vereelan PM	100, 200, 300 mg	Mylan	7/19/06	9/1/06	1:06-cv-00133	ND of WV	Irene M. Keeley	Dismissed 8/07	Mylan (9/06, D-8/07)
Vesicare	5, 10 mg	Teva	8/11/09	9/22/09	1:09-cv-08100	SD of NY	Sidney H. Stein	Pending	Teva (9/09)
Vfend (tab)	50, 200 mg	Mylan	Not Sued	Not Sued	NA	NA	NA	Settled 10/09	Mylan (NS)
Vfend (inj)	200mg/vial	Sandoz	Not Sued	Not Sued	NA	NA	NA	Pending	Sandoz (NS)
Viagra	25, 50 mg	Filed 10/25/04	NA	NA	NA	NA	NA	Pending	NA
Viagra	100 mg	Filed 11/19/04	NA	NA	NA	NA	NA	Pending	NA
Vigamox	0.5% solution	Teva	2/21/06	4/5/06	1:06-cv-00234	DE	Sue L. Robinson	Lost 10/09	Teva (4/06)
Vytorin	10/10, 10/20, 10/40, 10/80mg	Mylan	11/5/09	12/18/09	1:09-cv-00167	ND of WV	Irene M. Keeley	Pending	Mylan (12/09)
Welchol	625mg	Filed 7/1/09	NA	NA	NA	NA	NA	Pending	NA
Xalatan	2.5 ml	Par/Arrow	12/18/01	12/21/01	3:01-cv-06011	DE	Stanley R. Chesler	Lost 7/04; Upheld 8/05; Mandate 10/05	Par/Arrow (12/01),
Xeloda	150, 500 mg	Mylan	3/11/09	4/8/09	2:09-cv-01692	NJ	William J. Martini	Pending	Mylan (4/09), Teva (10/09), Roxane (12/09)
Xopenex neb	0.0103%, 0.021% and 0.042% solution	Breath Ltd	9/6/05	10/21/05	1:06-cv-10043	MA	Douglas P. Woodlock	Settled 5/08	Breath (10/05, S-4/08), Dey (2/06), Watson (3/06, NS), Barr (7/07, S-3/09)
Xopenex neb	0.25% solution	Dey	8/14/06	9/27/06	1:06-cv-00113	DE	Kent A. Jordan	Pending	Dey (9/06)
Xyzal tabs	5 mg	Perrigo/Synthon	2/28/08	4/10/08	1:08-cv-00207	DE	Gregory M. Sleet	Case Dropped 6/08	Synthon (4/08, D-6/08), Sun (5/08, D-5/09), Sandoz (6/08), Barr (7/08, D-4/09)
Xyzal oral sol.	0.5mg/mL	Perrigo/Synthon	5/5/09	6/17/09	5:09-cv-00264	ED of ND	W. Earl Britt	Pending	Synthon (6/09)
Yasmin	3 mg/0.03 mg	Barr	3/18/05	4/29/05	2:05-cv-02308	NJ	Peter G. Sheridan	Settled 6/08	Barr (3/05), Watson (4/08), Sandoz (4/08)
Yaz	3 mg/0.02 mg	Barr	Not Sued	Not Sued	NA	NA	NA	Settled 6/08	BRL (9/06-NS, S-6/08), WPI (11/07), Sandoz (7/08)
Zanaflex (caps)	2, 4, 6 mg	Apotex	8/31/07	10/11/07	2:07-cv-04937	NJ	Garrett E. Brown, Jr.	Pending	Apotex (10/07)
Zantac syrup	15 mg base/ml	Teva	2/5/04	3/18/04	1:04-cv-00171	DE	Kent A. Jordan	Pending	Teva (3/04), Cypress (6/07, D-1/08), Amneal Pharma (1/08)
Zegerid caps	20/1100, 40/1100, 20/1680 mg	Par	8/2/07	9/13/07	1:07-cv-00551	DE	Gregory M. Sleet	Pending	Par (9/07)
Zegerid suspension	40 mg/1680 mg per packet	Par	11/13/07	12/20/07	1:07-cv-00827	DE	Gregory M. Sleet	Pending	Par (12/07)
Zemplar (caps)	1, 2, 4mcg	Teva	10/8/08	11/20/08	1:08-cv-06659	ND of IN	Charles P. Kocoras	Pending	Teva (10/08)
Zemplar (inj)	0.002mg/mL in 1 mL vial and 0.005mg/mL	Sandoz	2/19/09	4/1/09	09-cv-00215	DE	Gregory M. Sleet	Pending	Sandoz (4/09); Teva (11/09)
Zetia	10 mg	Glenmark	2/9/07	3/22/07	2:07-cv-01334	SD of NY	Jose L. Linares	Pending	Glenmark (3/07)
Zometax (inj)	4mg base/5mL; 5mg	Teva	6/10/08	7/24/08	1:08-cv-00459	DE	Sue L. Robinson	Pending	Teva (7/08)
Zymar	0.3% solution drops	Apotex	10/17/07	11/29/07	1:07-cv-00779	DE	Sue L. Robinson	Pending	Apotex (11/07)
Zyvox (inj)	2mg/ml, 300ml bag	Filed 9/1/09	NA	NA	NA	NA	NA	Pending	NA
Zyvox (susp.)	100mg/5mL	Filed 8/3/09	NA	NA	NA	NA	NA	Pending	NA
Zyvox (tab)	600 mg	Filed 12/21/05	NA	NA	NA	NA	NA	Pending	NA

Source: PACER, Company reports, RBC Capital Markets estimates.



Appendix D: Litigation Scorecard History 2000-2009 (Complete)

	Lost	%	Won	%	Settled	%	Dropped	%	TOTAL	Success %
Actavis (total)	1	17%	2	33%	3	50%	0	0%	6	83%
<i>Alpharma</i>	0	0%	1	100%	0	0%	0	0%	1	100%
<i>Actavis</i>	1	20%	1	20%	3	60%	0	0%	5	80%
Alcon	0	0%	0	0%	1	100%	0	0%	1	100%
Amneal	0	0%	0	0%	1	100%	0	0%	1	100%
Amphastar	0	0%	1	100%	0	0%	0	0%	1	100%
Anchen	0	0%	1	25%	3	75%	0	0%	4	100%
Apotex	12	57%	2	10%	7	33%	0	0%	21	43%
Baxter	0	0%	1	100%	0	0%	0	0%	1	100%
Bedford	0	0%	0	0%	1	100%	0	0%	1	100%
Breath	0	0%	0	0%	1	100%	0	0%	1	100%
Caraco	0	0%	1	100%	0	0%	0	0%	1	100%
Cheminor	1	100%	0	0%	0	0%	0	0%	1	0%
Corepharma	0	0%	1	50%	1	50%	0	0%	2	100%
Covidien	0	0%	0	0%	1	100%	0	0%	1	100%
Cypress Pharma	0	0%	0	0%	1	100%	0	0%	1	100%
Dr. Reddy's	7	39%	2	11%	9	50%	0	0%	18	61%
Endo	0	0%	1	50%	1	50%	0	0%	2	100%
Exela	1	100%	0	0%	0	0%	0	0%	1	0%
Glenmark	1	33%	0	0%	2	67%	0	0%	3	67%
Hi Tech	1	100%	0	0%	0	0%	0	0%	1	0%
Hospira	1	33%	2	67%	0	0%	0	0%	3	67%
Impax	2	14%	4	29%	7	50%	1	7%	14	86%
KV Pharm	1	14%	1	14%	3	43%	2	29%	7	86%
Lupin	2	25%	1	13%	4	50%	1	13%	8	75%
Mylan	9	36%	7	28%	9	36%	0	0%	25	64%
Nostrum	1	100%	0	0%	0	0%	0	0%	1	0%
Orchid	0	0%	0	0%	2	100%	0	0%	2	100%
Par	2	13%	4	27%	9	60%	0	0%	15	87%
Paddock	0	0%	1	50%	1	50%	0	0%	2	100%
Perrigo	0	0%	1	13%	4	50%	3	38%	8	100%
Prasco	1	100%	0	0%	0	0%	0	0%	1	0%
Ranbaxy	7	37%	2	11%	9	47%	1	5%	19	63%
Roxane	1	33%	0	0%	2	67%	0	0%	3	67%
Sandoz (total)	3	13%	11	46%	9	38%	1	4%	24	88%
<i>Sandoz</i>	3	18%	6	35%	7	41%	1	6%	17	82%
<i>Eon Labs</i>	0	0%	5	71%	2	29%	0	0%	7	100%
Schwarz	1	50%	1	50%	0	0%	0	0%	2	50%
Sun	3	33%	1	11%	4	44%	1	11%	9	67%
Teva (total)	24	22%	27	25%	51	46%	8	7%	110	78%
<i>Teva</i>	17	25%	16	23%	31	45%	5	7%	69	75%
<i>Copley</i>	0	0%	1	50%	1	50%	0	0%	2	100%
<i>IVAX</i>	4	80%	1	20%	0	0%	0	0%	5	20%
<i>Barr</i>	3	9%	9	26%	19	56%	3	9%	34	91%
Tolmar	0	0%	0	0%	1	100%	0	0%	1	100%
Upsher Smith	0	0%	0	0%	2	100%	0	0%	2	100%
URL Pharma	2	40%	1	20%	1	20%	1	20%	5	60%
Watson (total)	4	10%	6	15%	23	59%	6	15%	39	90%
<i>Watson</i>	2	13%	0	0%	9	56%	5	31%	16	88%
<i>Andrx</i>	2	13%	6	40%	7	47%	0	0%	15	87%
<i>Cobalt</i>	0	0%	0	0%	7	88%	1	13%	8	100%
Wockhardt	0	0%	0	0%	4	100%	0	0%	4	100%
Zybus	1	100%	0	0%	0	0%	0	0%	1	0%
Generics Total	89	24%	82	22%	177	47%	25	7%	373	76%

Source: PACER, Company reports, RBC Capital Markets estimates.



Required Disclosures

Conflicts Disclosures

This product constitutes a compendium report (covers six or more subject companies). As such, RBC Capital Markets chooses to provide specific disclosures for the subject companies by reference. To access current disclosures for the subject companies, clients should refer to <http://www7.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?EntityID=1> or send a request to RBC CM Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7.

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

Distribution of Ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Top Pick/Outperform, Sector Perform and Underperform most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis (as described above).

Distribution of Ratings RBC Capital Markets, Equity Research				
Rating	Count	Percent	Investment Banking Serv./Past 12 Mos.	
			Count	Percent
BUY[TP/O]	587	49.50	182	31.01
HOLD[SP]	529	44.60	120	22.68
SELL[U]	71	6.00	4	5.63

Conflicts Policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to

<https://www.rbccm.com/global/file-414164.pdf>

or send a request to RBC CM Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

Dissemination of Research and Short-Term Trading Calls

RBC Capital Markets endeavours to make all reasonable efforts to provide research simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. RBC Capital Markets' research is posted to our proprietary websites to ensure eligible clients receive coverage initiations and changes in rating, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax or regular mail. Clients may also receive our research via third party vendors. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets research.

RBC Capital Markets also provides eligible clients with access to a database which may contain Short-Term trading calls on certain of the subject companies for which it currently provides equity research coverage. The database may be accessed via the following hyperlink <https://www2.rbccm.com/cmonline/index.html>. The information regarding Short-Term trading calls accessible through the database does not constitute a research report. These Short-Term trading calls are not formal ratings and reflect the research analyst's views with respect to market and trading events in the coming days or weeks and, as such, may differ from the price targets and recommendations in our published research reports reflecting the research analyst's views of the longer-term (one year) prospects of the subject company. Thus, it is possible that a subject company's common equity that is considered a long-term 'sector perform' or even an 'underperform' might be a Short-Term buying opportunity as a result of temporary selling pressure in the market; conversely, a subject company's common equity rated a long-term 'outperform' could be considered susceptible to a Short-Term downward price correction.

Analyst Certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.



Disclaimer

RBC Capital Markets is the business name used by certain subsidiaries of Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets Corporation, Royal Bank of Canada Europe Limited and Royal Bank of Canada - Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior consent of RBC Capital Markets.

Additional information is available on request.

To U.S. Residents:

This publication has been approved by RBC Capital Markets Corporation (member FINRA, NYSE), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets Corporation.

To Canadian Residents:

This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

To U.K. Residents:

This publication has been approved by Royal Bank of Canada Europe Limited ('RBCCEL') which is authorized and regulated by Financial Services Authority ('FSA'), in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FSA. However, targeted distribution may be made to selected retail clients of RBC and its affiliates. RBCCEL accepts responsibility for this report and its dissemination in the United Kingdom.

To Persons Receiving This Advice in Australia:

This material has been distributed in Australia by Royal Bank of Canada - Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product.

To Hong Kong Residents:

This publication is distributed in Hong Kong by RBC Investment Services (Asia) Limited and RBC Investment Management (Asia) Limited, licensed corporations under the Securities and Futures Ordinance or, by Royal Bank of Canada, Hong Kong Branch, a registered institution under the Securities and Futures Ordinance. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact RBC Investment Services (Asia) Limited, RBC Investment Management (Asia) Limited or Royal Bank of Canada, Hong Kong Branch at 17/Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (telephone number is 2848-1388).

To Singapore Residents:

This publication is distributed in Singapore by RBC (Singapore Branch) and RBC (Asia) Limited, registered entities granted offshore bank status by the Monetary Authority of Singapore. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance.

®Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.

Copyright © RBC Capital Markets Corporation 2010 - Member SIPC

Copyright © RBC Dominion Securities Inc. 2010 - Member CIPF

Copyright © Royal Bank of Canada Europe Limited 2010

Copyright © Royal Bank of Canada 2010

All rights reserved

